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The glycine receptor (GlyR) is a ligand-gated chloride channel that mediates 
inhibitory neurotransmission in the brain and spinal cord.  Numerous allosteric 
modulators act on the GlyR including divalent cations, such as zinc, as well as drugs of 
abuse including ethanol, inhalants, anesthetics and cannabinoids.  GlyRs mediate some of 
the rewarding effects of addictive drugs and modulate drug related behaviors through 
activity in the mesolimbic dopamine reward pathway.  GlyR activity, however, can differ 
depending on whether the receptor is activated by the high-efficacy agonist, glycine, or 
taurine which has much lower efficacy at wild-type GlyRs.  As glycine and taurine are 
believed to activate the GlyR in vivo, it is crucial that we understand receptor function 
and allosteric modulation of receptors in response to both agonists.  We used two-
electrode voltage-clamp electrophysiology in Xenopus laevis oocytes to study the effects 
of zinc and ethanol on wildtype glycine receptors activated by glycine or taurine.  We 
determined that the magnitude of allosteric modulation was higher, overall, at taurine-
 viii 
gated receptors and hypothesized that this may be related to the difference in efficacies.  
Considering that GlyR mutants can affect agonist sensitivity and the response to allosteric 
modulators, we wondered whether changes in allosteric modulation at mutant receptors 
could be due to changes in agonist efficacy caused by these mutations.  We tested this 
hypothesis by characterizing ethanol and zinc modulation of taurine currents at GlyR 
mutants that showed an increase (1W170S) or decrease (1A52S) in taurine efficacy.  We 
found that the W170S mutation increases the relative efficacy of taurine to a level that is 
comparable with glycine and abolishes ethanol enhancement of maximally-effective 
taurine currents.  We determined that the difference in ethanol potentiation of low taurine 
currents between W170S and WT receptors is due to zinc enhancement of WT currents.  
Ethanol modulation of these receptors was equal in the presence of tricine.  This suggests 
that ethanol also increases taurine affinity at W170S.  A52S, on the other hand, displayed 
reduced taurine efficacy and increased ethanol modulation.  This work provides evidence 
of a mechanism by which the degree of allosteric modulation of glycine receptor function 
is dependent on agonist efficacy. 
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Chapter 1: Introduction 
1.1 - Cys-Loop Family of Ligand-Gated Ion Channels 
The nervous system encompasses a complex network of specialized cells 
responsible for transmitting information throughout the body using a combination of 
chemical and electrical signals.  Ligand-gated ion channels (LGICs) receive chemicals 
signals in the form of specific ligands that bind to the channel, regulating rapid ion flux 
across the cell membrane.  This, in turn, modulates bioelectrical communication by 
generating changes in membrane potential on the order of milliseconds (Langosch et al., 
1990).  Cys-loop receptors (CLRs) form a family of ligand-gated ion channels (LGICs) 
that share a similar structure (Figure 1.1).  Cation-conducting CLRs include nicotinic 
acetylcholine receptors (nACh), serotonin type three receptors (5-HT3), and glutamate-
gated chloride channels (GluCl) receptors.  Additional members conduct anions such as 
GABA receptors (GABAAR, GABACR), glycine receptors (GlyR), modulation of 
locomotor defective channels (MOD-1) and excitatory GABA-gated cation channels 
(EXP-1) (Lester et al., 2004; Pless et al., 2008). 
All CLRs receptors are homo- or heteromeric pentamers with subunits arranged 
radially around an ion conducting pore.   Each subunit contains of a large extracellular 
domain (ECD) composed primarily of beta sheets and contains the signature cys-loop, a 
closed loop formed by a disulfide bond between cysteine residues (Sine and Engle, 
2006).  The extracellular domain (ECD) contains binding sites for agonists, antagonists 
and various modulators.  Glycine receptors contain an additional cys-loop that contributes 
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to the glycine binding domain (Webb and Lynch, 2007).  Homologous receptors have 
also been identified in prokaryotes.  ELIC and GLIC receptors, found in Erwinia 
chrysanthemi and Gloeobacter violaceus, respectively, share a similar structure with 
CLRs but lack the characteristic cys-loop found in eukaryotic channels (daCosta and 
Baenziger, 2013; Lester et al., 2004; Miller and Smart, 2010; Nys et al., 2013). 
The membrane-spanning region of each subunit is composed of four -helices 
(TM1-4) arranged clockwise with the second transmembrane helix (TM2) from each 
subunit lining a central pore and the fourth transmembrane helix facing the plasma 
membrane.  There is also an intracellular domain in each subunit connecting TM3 and 
TM4 which varies considerably in size between CLRs and is involved in modulation of 
receptor function (Burgos et al., 2015; Sine and Engle, 2006; Webb and Lynch, 2007). 
A great deal of structural information has been gleaned from the crystal structure 
of the Acetylcholine Binding Protein (AChBP) from Lymnea stagnalis which shares 20-
24% amino acid sequence homology with nAChR (Colquhoun and Sivilotti, 2004; Webb 
and Lynch, 2007).  Like CLRs, the AChBP is pentameric with agonist binding sites 
located at subunit interfaces.  Not all subunits contribute to agonist binding and, due to 
variations in subunit composition, not all intersubunit interfaces and binding sites on a 
given receptor are identical (Miller and Smart, 2010; Shan et al., 2003).  The nAChR is 
composed of two alpha and three non-alpha subunits and has two agonist binding sites 
whereas homomeric CLRs contain five identical binding sites (Colquhoun and Sivilotti, 
2004).   
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A cation- interaction between each bound agonist and an aromatic residue within 
the binding pocket is highly conserved among CLRs, although the exact location of the 
critical aromatic amino acid varies among members.  In nACh and 5-HT3 receptors a 
tryptophan residue in Loop B forms this critical interaction while a tyrosine in Loop A 
performs the same function in GABAARs.  In GlyRs, this bond involves a phenylalanine 
in Loop B (Miller and Smart, 2010; Pless et al., 2008).  Additional aromatic amino acids 
in the ligand binding site contribute to ligand recognition (Nys et al., 2013). 
All CLRs require the presence of at least two bound agonist molecules for full 
activation.  After ligand binding, the signal is conveyed to the channel within 
microseconds across a distance of ~50-60 Å (Miller and Smart, 2010; Sine and Engle, 
2006).  Receptor activation is believed to involve a series of structural changes described 
as a ‘conformational wave’ that originates at the binding site and propagates across the 
receptor (Grossman et al., 2000).  This idea was further supported by rate-equilibrium 
free energy relationship (REFER) experiments that modeled the gating process as a series 
of domain shifts (Sine and Engle, 2006).  
Ligand binding is immediately followed by the movement of Loop C, closing the 
binding pocket.  Movement of Loop A, which normally helps stabilize the receptor in the 
closed state, also occurs early in the activation process (Miller and Smart, 2010).  
Conveying this information to the pore requires interactions between the ECD and 
transmembrane domains that are crucial for channel gating.  Interactions between 
residues in the LBD between strands 1 and 2, 8 and 9, as well as the cys-loop, and the 
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M2-M3 linker have all been shown to contribute to the gating process (Sine and Engle, 
2006). 
The channel forming TM2 helices from each subunit are bent at the midpoint in 
the 9’ to 13’ region, with the extracellular halves of each tilted away from each other 
such that the center of the pore is more constricted than the outer regions (Webb and 
Lynch, 2007).  The ion conduction pathway consists of 7 rings of amino acids from the 
M2 helices that are oriented into the lumen of the pore (Nys et al., 2013).  Hydrophobic 
interactions among a conserved ring of leucine residues at the 9’ position form part of the 
principal gate that restricts ion movement through the channel when in the closed state 
(Labarca et al., 1995; Miller and Smart, 2010).  Rings of charged residues at either end of 
the channel help determine ion selectivity while charged residues at the -1’ position 
further assist in charge discrimination.  The ECD may also contribute to rapid 
conductance by helping to concentrate ions in the vestibule.  (Miller and Smart, 2010; 
Sine and Engle, 2006) 
Based on the cryo-EM structure of the nAChR in the open state, we know that 
pore opening involves a clockwise rotation and outward tilt of each M2 region toward the 
M1 and M3 helices that widens the constriction point from 3 Å in the closed state to ~8 Å 
in the open state (daCosta and Baenziger, 2013; Miller and Smart, 2010; Sine and Engle, 
2006).  This flexibility of the M2 helices is partially dependent on highly conserved 
glycine residues in the M1-M2 and M2-M3 loops (Miller and Smart, 2010). 
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Figure 1.1: Basic Structure of a Cys-loop Receptor 
 
Left: Structure of the nicotinic acetylcholine receptor (nAChR) from Torpedo (Protein 
Data Bank [PDB] ID code 2BG9.  Side view of the extracellular agonist binding domain 
(red), the transmembrane region containing the pore (blue) and the intracellular 
cytoplasmic domain (green).  Tan spheres in the ECD correspond to residues that form 
the ligand binding site and yellow spheres in the transmembrane domain represent R 
groups that form the channel gate. 
Top Right: nAChR viewed from outside the cell showing the extracellular domain.  Each 
subunit is shown in a different color.   
Bottom Right: Top view of the transmembrane domain showing the clockwise 
arrangement of the TM1-4 helices for each subunit. 
Adapted from Da Costa, C.J.B., Baenziger, J.E., 2013. Gating of pentameric ligand-
gated ion channels: structural insights and ambiguities. Structure. 21, 1271-1283. 
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1.2  - The Glycine Receptor 
1.2.1 - Basic Structure  
 The Glycine receptor (GlyR) is responsible for inhibitory neurotransmission in the 
brain and spinal cord.  GlyR  and  subunits were first isolated from mammalian spinal 
cord via affinity purification (Betz, 1987).  Four  subunits have been identified (1-4) 
that share 80-90% sequence homology (Betz and Laube, 2006) and are believed to have 
developed as a result of gene duplication events.  A single  subunit has been identified 
which shares approximately 47% sequence identity with the α1 subunit and serves to 
anchor heteromeric receptors to the cytoskeleton of post-synaptic neurons through its 
interaction with the protein gephyrin (Lynch, 2004).  and  form functional 
receptors in humans.  The α4 subunit, although found in mice, chicks and zebrafish, is 
only a pseudogene in humans (Bowery and Smart 2006; Lynch 2009, 2004).   
GlyRs occur as homomeric receptors composed of a single type of  subunit or as 
αβ heteromers.   Kuhse et al. (1993) constructed chimeric receptors of  and  subunits in 
order to identify regions of the receptor involved in subunit assembly.  They discovered a 
portion of the ECD in the  subunit that is found at subunit interfaces and is required for 
the invariant stoichiometric assembly of heteromeric GlyR.  They reported that functional 
heteromeric GlyRs are composed of 3 and 2 subunits.  However, the exact 
stoichiometery of heteromeric GlyRs is still debated and has been reported as both 3α:2β 
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(Becker et al., 1988, Betz et al., 1993, Kuhse et al., 1993; Burzomato et al., 2003) and 
2α:3β (Grudzinska et al., 2005).   
 The extracellular domain of the GlyR forms a barrel-like structure consisting of 
10 -strands and two -helices at the N-terminus between the 3 and 4 strands.  Agonist 
binding sites are located between adjacent subunits and are formed by loops A/B/C of the 
principal (+) face and involve a number of residues including: F44, F63, R65, L117, 
L127, and S129 in the 1 subunit.  The complementary face of the LBD is formed by -
strands D/E/F and involves F159, Y202, T204 and F207 (Burgos et al., 2016).  In GlyRs 
containing l subunits, Phe159 forms a crucial cation- bond with the amine nitrogen of 
the agonist (Miller and Smart, 2010; Pless et al., 2008).  Based on the model proposed by 
Colquhoun and Sivilotti (2004) GlyRs require a minimum of 3 bound agonists for full 
activation. 
1.2.2 - Distribution and Function 
GlyR subunits are unevenly distributed in the Central Nervous System (CNS).  
Early in situ hybridization experiments in rats showed l transcripts in the spinal cord, 
brain stem, thalamus, hypothalamus and superior and inferior colliculi.  2 mRNAs were 
identified in the cerebral cortex, hippocampus, thalamus, hypothalamus, geniculate 
nuclei, and, to a lesser extent, in the brain stem and spinal cord, while 3 was found in 
the cerebellum, olfactory bulb, hippocampus, hypothalamus, mesencephalon and spinal 
cord, particularly in the dorsal horn.  Distribution of transcripts for the  subunit showed 
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widespread distribution throughout the brain and spinal cord (Betz et al., 1993; Malosia 
et al., 1991a).   
Baer et al., 2009 used immunohistochemistry in conjunction with light and 
confocal laser scanning microscopy to probe the cellular and subcellular localization of 
GlyRs in the human forebrain, brainstem and spinal cord.  This study demonstrated a 
similar GlyR distribution to that previously described in immunohistochemical studies of 
the rat brainstem and spinal cord.  GlyRs have also been identified in the nucleus 
accumbens and prefrontal cortex (Baer et al. 2009; Jonsson et al. 2012a, 2009b; Lynch 
2004).  The  subunit is expressed throughout the retina while  subunits, which are also 
present at high levels, have distinct patterns of distribution.  1 mRNA has been found in 
bipolar and some ganglion cells while 2 subunits are present in amacrine cells of the 
inner nuclear layer and the ganglion cell layer.  3 are distributed throughout the entire 
inner nuclear layer and, to a lower degree in the ganglion cell layer (Betz and Laube, 
2006).  Glycine receptors also perform important functions outside of the CNS.  
Extrasynaptic GlyR are involved in the acrosomal reaction that fuses sperm and egg and 
have been found in macrophages and leucocytes where they help modulate the 
inflammatory immune response (Webb and Lynch, 2007). 
Expression of the sodium-potassium-chloride cotransporter (NKCC1) is high in 
the embryonic neurons, resulting in the accumulation of chloride inside the cell.  
Activation of 2-containing GlyRs on these cell results in outward flux of Cl- which 
causes depolarization.  This GlyR-mediated excitation is believed to be crucial for 
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neuronal differentiation and synaptogenesis during early development; however, due to 
the low concentration of glycine in the neocortex, it is likely that GlyR in this region are 
being activated by a different agonist.  Taurine is present at high concentrations 
throughout the brain and taurine deprivation is known to lead to defects in cortical 
development, making it a likely candidate (Flint et al., 1998; Webb and Lynch, 2007).  In 
later stages of development NKCC1 expression declines while expression of the K+/Cl- 
cotransporter (KCC2) increases, causing a reduction in intracellular chloride 
concentrations, eventually reaching concentrations of 3-5 mM in adult neurons.   Due to 
this shift in the chloride gradient, activation of GlyRs in mature neurons produce an 
influx of Cl- which hyperpolarizes the cell and, as a result, causes inhibition (Aguayo et 
al., 2004; Webb and Lynch, 2007). 
Despite their high sequence homology, the various subunits that make up glycine 
receptors differ in their sensitivities and responses to different agonists, antagonists and 
modulators.  Differential expression of GlyR subtypes in different brain regions further 
adds to their functional diversity in vivo.  The expression and distribution of GlyR 
subunits is also known to change during development.   
In the spinal cord, α2 homomers present in early development are largely replaced 
by α1β heteromers in adults.   expression is low in early development and increases 
rapidly after birth (Webb and Lynch, 2007).  There are two isoforms of 1 with similar 
distribution patterns (Lynch, 2004).  The human WT 1 isoform 1 contains an 8-amino 
acid insertion in the intracellular loop between TM3 and TM4 that includes a potential 
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protein kinase phosphorylation consensus sequence.  The same insertion can be found in 
the rat 1ins variant (Lynch, 2004; Malosia et al., 1991a, 1991b).  
GlyRs composed of 2 subunits predominate during embryonic development but 
their expression declines rapidly after birth (Webb and Lynch, 2007).  In the adult 
forebrain, however, the α2 subunit persists as a heteromer with the β subunit (Jonsson et 
al., 2012).  Homomeric 2 receptors are also maintained at high levels in the adult retina 
and auditory brain stem (Lynch, 2004).  In adults, 2 homomeric receptors are mainly 
found in extrasynaptic locations.  2 homomeric GlyRs expressed heterologously in 
Xenopus laevis oocytes show a decreased response to the partial agonists taurine and -
alanine relative to glycine, as well as reduced sensitivity to the antagonist strychnine 
compared to 1 (Schmieden et al., 1992). 
In rats, the 2 subunit also has two spice variants, 2A and 2B, that differ by 
two residues at positions 58 and 59 in the NTD.  The B variant possesses a valine at 
position 58 and a threonine at position 59 while the 2A variant contains isoleucine and 
alanine, respectively (Miller et al., 2004).  In embryonic tissues, the 2A-isoform 
predominates whereas 2B is more highly expressed in adults (Lynch, 2004).  Glycine, 
-alanine and taurine EC50 values are left-shifted in 2B relative to 2A.  Furthermore, 
currents produced by maximally effective concentrations of taurine at 2B are 
comparable to those produced by saturating concentrations of glycine.  In 2A, maximal 
taurine currents are lower than glycine currents indicating that taurine has lower efficacy 
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at this isoform.  Both isoforms exhibit similar sensitivity to strychnine and zinc but 2A 
is ~5X more sensitive to picrotoxin (PTX) (Miller et al., 2004).  An additional variant of 
the 2 subunit, 2*, differs from wildtype by a single point mutation G167E that renders 
it insensitive to strychnine (Lynch, 2004). 
Expression of the 3 subunit increases during development but is only detected 
postnatally (Malosia et al., 1991a; Burgos et al., 2016).  The expression pattern of 3 
mirrors that of 1 although at lower levels outside of the dorsal horn (Webb and Lynch, 
2007).  In the hippocampus, 3 homomeric receptors are mainly extrasynaptic where 
they are believed to play a role in tonic inhibition along with 2 homomeric GlyRs 
(Langlhofer and Villmann, 2016).  The human 3 subunit has two spice variants, 3K 
(short) and 3L (long), that are similarly distributed (Lynch, 2004).  3L, as well as the 
rat 3 subunit, contains a 15-amino acid splice cassette in the intracellular TM3-4 loop 
that may provide up to three phosphorylation consensus sites at T358, Y367 and S370.  
This insertion has a marked effect on receptor desensitization.  3K exhibits currents that 
quickly desensitize while 3L shows almost no desensitization.  When this same 15-
residue cassette was inserted into the 1 subunit, it similarly caused a substantial 
decrease in desensitization (Langlhofer and Villmann, 2016; Lynch, 2004). 
The  subunit has the most widespread distribution of any GlyR subunit, with 
transcripts found throughout the brain and spinal cord, both prenatally and in adults 
(Lynch, 2004; Webb and Lynch, 2007).  As with 1, expression levels of the  subunit 
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are lower early in development, and increase significantly after birth.   An 18-residue 
gephyrin binding domain in the TM3-4 loop has been shown to concentrate heteromeric 
GlyRs at postsynaptic locations (Lynch, 2004; Meyer et al., 1995). 
1.2.3 - Activation, Gating and Desensitization 
Glycine receptors are activated by multiple amino acids in the following order, by 
potency: glycine, -alanine, taurine, alanine, serine, proline and GABA (Betz, 1987).  
Taurine (2-aminoethane sulfonic acid) is one of the most abundant amino acids in muscle 
tissue and organs.  It is the most abundant amino acid in the neonatal brain, present at 
concentrations similar to glutamate in the cerebral cortex of developing rats, and is 
necessary for normal cortical development.  By comparison, the concentration of glycine 
in this area is ten times lower (Flint et al., 1998).  Taurine concentration in the brain 
decreases during later development.  In adult rats, taurine levels are ~25% of those found 
in newborn animals (Agrawal et al., 1971).  Despite this, it remains the second most 
abundant neurotransmitter in the adult brain where extracellular concentrations are in the 
millimolar range (Mori et al., 2002). 
Taurine is synthesized from cysteine and methionine within the body with 
cysteinesulfinic acid decarboxylase (CSD) performing the rate limiting step.  Not 
surprisingly, CSD is found in numerous tissues such as the liver, kidney, reproductive 
organs and brain, highlighting the importance of taurine in these areas.  CSD levels are 
relatively low humans and other primates but taurine is readily available in diets 
containing meat and seafood (Ripps and Shen, 2012).  A typical American diet provides 
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~123-178 mg of taurine per day compared to ~17 mg in a vegetarian diet.  As a result, 
circulating taurine levels in vegetarians are lower than in their meat-eating counterparts 
(Caine and Ceracioti, 2016). 
 Although taurine is not incorporated into proteins, it performs numerous other 
functions.  Taurine has anti-inflammatory and cytoprotective properties and acts to 
regulate cell volume and intracellular calcium levels.  Taurine deficiency has been liked 
to cardiomyopathy, renal dysfunction, pancreatic  cell malfunction, retinal damage and 
developmental abnormalities in the brain (Caine and Geracioti, 2016; Ripps and Shen, 
2012). 
Glycine is generally considered to be the primary endogenous agonist of the 
glycine receptor; however, there is increasing evidence that the taurine may also be an 
important agonist at GlyRs in the CNS (Albrecht and Schousboe 2005; Ericson et al., 
2006; Flint et al., 1998; Wang et al., 2005).  This is supported by the research of Mori et 
al. (2002) who showed that inhibiting taurine transporters with guanidinoethanesulfonic 
acid (GES) induced a strychnine-sensitive chloride current in hippocampal organotypic 
slice cultures, suggesting that taurine may play a role in maintaining tonic inhibition in 
this region.  Wang et al. (2005) later identified taurine-sensitive GlyRs on a subset of 
dopamine neurons in the VTA of rats which are also subject to tonic inhibition.   
Taurine is considered a partial agonist at the GlyR with approximately 5% of the 
efficacy of glycine (Lape et al., 2008).  At saturating concentrations, the probability of 
finding a fully-liganded  GlyR receptor in the open state is ~54% for taurine and 96% 
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for glycine, despite the fact that opening and shutting rates are similar for the two 
agonists (Lape et al., 2008).  In early models, partial agonism was believed to be a result 
of the reduced ability of the bound channel to transition to the open conformation once 
bound by agonist.  Lape et al. (2008) proposed a new model, based on single channel 
recordings of taurine- and glycine-activated GlyR in HEK293 cells.   They postulated the 
existence of an additional transition state, called the ‘flipped’ state, that occurs after 
ligand binding and precedes channel opening.  In this model, the lower efficacy of a 
partial agonist is due to having a lower equilibrium constant for entering this pre-open 
‘flipped’ state (Figure 1.2). They demonstrated this experimentally, showing that glycine 
has a much higher equilibrium constant for flipping than taurine (Figure 1.2 from Lape et 
al, 2008).  Once in the ‘flipped’ conformation, however, both glycine- and taurine-bound 
channels open at similar rates.   
 Strychnine is a convulsive alkaloid from the Strychnos nux vomica plant and 
competitive inhibitor of GlyRs with high (nM) affinity for all GlyR isoforms (Betz, 1987; 
Langosh et al., 1990; Webb and Lynch, 2007).  This property was exploited early on to 
purify GlyRs from tissue preparations and to differentiate glycinergic from GABAergic 
activity (Betz et al., 1993; Lynch, 2004).  Strychnine binds between residues 170 and 220 
of the 1 subunit and shares an overlapping but non-identical binding site with GlyR 
agonists (Kuhse et al., 1995).   
 Picrotoxin (PTX), present in plants in the moonseed family, consists of an equal 
mix of picrotin and picrotoxinin and is a potent non-specific inhibitor of anion-
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conducting CLRs.  At GABAARs, PTX acts as a pore blocker but functions as an 
allosteric inhibitor at  subunit-containing GlyRs.  PTX sensitivity is determined by the 
2’ and 6’ residues in the pore-forming M2 domain.  Due to sequence differences between 
 and  subunits in this area, the PTX sensitivity of heteromeric GlyRs is 50-100x lower 
than homomeric receptors, making it a useful tool for detecting the presence of the  
subunit (Betz, 1993; Webb and Lynch, 2007). 
Voltage-clamp fluorometry experiments performed on 1 GlyR expressed in 
oocytes were used to elucidate the structural changes that occur during agonist and 
antagonist binding and subsequently, signal transduction.  Pless et al. (2009a,b) measured 
agonist-induced changes in response to activation by glycine, taurine and -alanine, 
agonists that differ in efficacy, during the transition between the closed and ‘flipped’ 
states.  Conformational changes caused by glycine and strychnine were also compared.  
They observed movements of Loops C and F and the pre-M1 domain that were 
indistinguishable between agonists.  Loop 2 also displayed agonist-induced changes in 
conformation in the environment of A52, however, the magnitude of these changes were 
unequal and directly proportional to the efficacy each agonist.  This further supports the 
findings of Crawford et al. (2008) who employed cysteine-scanning mutagenesis to 
determine that that structural differences in Loop 2 had significant, and sometimes 
opposite effects on glycine sensitivity.  Taken together, these studies provide evidence of 
agonist-specific differences in a signal transduction mechanism that involves the Loop 2 
domain.  Differences were also observed between glycine and strychnine at loops 2, D, E 
16 
 
and the pre-M1 domain indicating that structural rearrangements in these regions may be 
involved in receptor activation.   
Further advances in our understanding of GlyR activation came from the Cryo-
EM structures of the zebrafish 1 homomeric glycine receptor bound to glycine and 
strychnine, published by Du and colleagues (2015).  Following binding of agonists to the 
ECD, the upper portion of the ECD twists anticlockwise relative to the pore axis with the 
lower region tilting inwards toward the center of the pore.  This motion causes significant 
displacement of Loop C inward, such that it closes over the ligand binding pocket and 
displaces the 8-9 loop which is, in turn, connected to the pre-M1 loop causing it to also 
shift.  This leads to rotation of the M1 helix which is connected to the intracellular 
portion of M2.  As a result, the lower portion of M2 is pushed inward towards the pore 
axis.  Movement of the 8-9 loop also shifts the cys-loop.  This allows the M2-M3 
linker to interact with the 1-2 loop in the ECD which forces the upper region of M2 
outwards such that the extracellular half of the TMD is wider than the intracellular 
portion.  This interaction, involving proline 291 and threonine 70, helps to stabilize the 
receptor in the open state.  Overall, this results in a 49˚ tilt in the outer portion of the M2 
helix relative to the closed conformation.  Expansion of the pore causes the rotation of a 
ring of leucine residues at the 9’ position away from the pore axis, widening the channel 
to up to 4 or 5 Å.  In the open state, the greatest constriction point occurs at the -2’ 
position which has a radius of 4.4 Å (Du et al., 2015). 
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 Desensitization occurs when a receptor with a previously open channel enters a 
non-conducting conformation, despite the continued presence of bound agonist.  The rate 
at which the receptor transitions to, and recovers from, a desensitized state can have 
profound effects on overall function, including the frequency and amplitude of 
glycinergic currents.  The general mechanism believed to be responsible for 
desensitization in Cys-loop receptors involves interactions between amino acids in TM2 
and TM3 nearer the intracellular region of the channel, between the 2’ and 9’ positions, 
that constitute a specific ‘desensitization gate’ that is largely influenced by the 
intracellular domains of the receptor (Gielen et al., 2015, Lynch, 2004, Nys et al., 2013).  
For example, the long isoform of the 3 subunit, 3L, contains a 15-residue splice 
cassette in the intracellular domain which renders these receptors largely insensitive to 
desensitization.  Point mutations in the TM1-TM2 of 1 GlyRs, found in some cases of 
human hyperekplexia, such as I244N and P250T, have the opposite effect (Lynch, 2004).  
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Figure 1.2: Model of the ‘flipped’ mechanism for partial agonism 
 
Energy diagrams of the transitions between the closed, flipped, and open states.  Taurine 
has a much higher energy barrier for reaching the flipped conformation than glycine but 
the subsequent transitions from flipped to open are similar.  Adapted from Lape, R., 
Colquhoun, D., Sivilotti, L.G., 2008. On the nature of partial agonism in the nicotinic 
receptor superfamily. Nature. 454, 722-727. 
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1.2.4 - Intracellular Domain  
Regions of the large intracellular loop (IL) connecting TM3 to TM4 helps 
determine the properties of specific GlyR subunits.  The scaffolding protein gephyrin 
interacts with an 18 residue portion of the  subunit anchoring the receptor to cytoskeletal 
filaments (Meyer et al., 1995).  Gephyrin is also a key mediator of receptor trafficking 
through interactions with the microtubule-associated motor proteins KIF5 and dlc1/2.  
Similarly, a conserved poly-proline helix type II recognition motif, 384KxxPxxPxxP394 
found in the  subunit, interacts with Syndapin which is also involved in receptor 
trafficking (Langlhofer and Villmann, 2016).  Thus, the IL plays a critical role in GlyR 
surface expression and the formation of inhibitory synapses.  The 15-amino acid insertion 
in the IL of 3L helps targets these subunits to presynaptic sites through interactions w/ 
the vesicular trafficking protein Sec8.  Mutations in the TM3-TM4 loop that are linked to 
defects in receptor trafficking and subsequent accumulation in the ER and Golgi have 
been found in cases of recessive hyperekplexia (Langlhofer and Villmann, 2016). 
The GlyR-IL serves as a site for posttranslational modification including 
ubiquitination of lysine residues and phosphorylation by protein kinase A (PKA), protein 
kinase C (PKC) and tyrosine kinases, whose effects differ depending on the GlyR 
subtype and location (Burgos et al., 2015).  Increased PKA activity in cultivated brain 
stem neurons enhances glycine-evoked currents (Kuhse et al., 1993).  PKC-dependent 
phosphorylation of S391 in the 1 subunit increases the rate of GlyR internalization by 
endocytosis.  Phosphorylation of S403 in the  subunit impairs the ability of the receptor 
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to bind gephyrin, causing a decrease the synaptic GlyR density by diffusion away from 
the synapse.  The 3 subunit also possess a unique PKA consensus sequence involving 
S346.  Phosphorylation of this site causes receptor internalization which contributes to 
PGE2-mediated inhibition of glycinergic neurotransmission known to contribute to 
inflammatory pain sensitization (Langlhofer and Villmann, 2016).  
Stretches of highly conserved basic amino acids located near the pore affect ion 
selectivity and conductance and may be involved in the rearrangement of M3 and M4 
during channel gating.  There is also evidence that 316RFRRK320 and 385KK386 in the 
GlyR-IL of the 1 subunit interacts with Gwhich may be critical for the enhancing 
effects of ethanol at these receptors.  K385 in this region has also been linked to allosteric 
modulation of GlyRs by endocannabinoids (Langlhofer and Villmann, 2016).   
1.3 - GlyR Modulation 
GlyR function is affected by a variety of endogenous compounds such as zinc, 
glutamate, endocannabinoids and neuroactive steroids (Yevenes, et.al., 2011) as well as 
numerous exogenous modulators including alcohols, anesthetics, inhalants and 
cannabinoids that interact with regions of the receptor outside of the orthosteric agonist 
binding site (Figure 1.3) (Beckstead et al., 2000; Harvey et al., 1999; Kirson et al., 2013, 
2012; Mascia et al. 1996; Mihic et al., 1997, Xiong et al., 2011).  Allosteric modulators 
shift glycine concentration-response curves either to the left or to the right but have 
negligible effects at maximally-effective glycine concentrations.  Work in our lab, 
however, determined that ethanol, volatile anesthetics, inhaled drugs of abuse and zinc 
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are able to enhance GlyR currents elicited by maximally-effective concentrations of the 
partial agonist taurine (Kirson et al. 2013a, 2012b).  This suggests that the mechanism of 
allosteric modulation of GlyRs depends on whether the receptor is activated by glycine or 
taurine.  
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Figure 1.3: Residues involved in glycine receptor activation and modulation 
 
Illustration of a single 1 GlyR subunit embedded in the plasma membrane showing the 
location of important residues involved in activation and modulation of the receptor in 
the extracellular domain (ECD), transmembrane domain (TMD) and intracellular domain 
(ICD).  Black and brown circles represent cysteine residues forming disulfide bonds and 
the N-glycosylation site, respectively.  Locations of naturally occurring murine 
spasmodic and human hyperekeplexia mutations are highlighted in yellow.  Blue residues 
are involved in binding agonists and antagonists.  Residues involved in the actions of 
alcohols and anesthetics are shown in green while those involved in zinc modulation are 
pink.  G254 (red) determines pore conductance and sensitivity to pore blockage by 
cyanotriphenylborate (CTB).  Grey residues in M2 are believed to line the pore.   
Adapted from Laube, B., Maksay, Gl., Schemm, R., Betz, H., 2002. Modulation of glycine 
receptor function: a novel approach for therapeutic intervention at inhibitory synapses. 
TRENDS Pharmacol. Sci. 23, 519-527. 
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1.3.1 - Inhalants and Anesthetics 
Anesthetics and inhaled drugs of abuse act as positive allosteric modulators of 
GlyR and GABAAR function.  Isoflurane increased the frequency of mIPSCs in rat 
trigeminal nucleus and spinal motoneurons and reduced the firing of spontaneous action 
potentials in rat spinal slice cultures (Burgos et al., 2016, 2015).  The binding site for 
volatile anesthetics such as isoflurane, enflurane, halothane and sevoflurane is located in 
an intrasubunit cavity in the transmembrane domain of GlyRs and GABAARs.  Mihic et 
al. (1997) created chimeric receptors using the GlyR 1 subunit, which is positively 
modulated by anesthetics and alcohols, and the homologous 1 GABACR, which is 
inhibited by these compounds, to identify a 45 residue stretch of amino acids in the 
transmembrane domain of these receptors that confers sensitivity to ethanol, enflurane 
and isoflurane.  They then utilized site-directed mutagenesis to pinpoint S267 in TM2 and 
A288 in TM3 of the 1 GlyR (and corresponding residues in GABAAR) as critical for 
these actions.  Beckstead et al. (2002) expanded on this work to show that the site of 
action of inhalants such as TCE, TCY and Toluene overlap with the same binding pocket 
as volatile anesthetics including the serine residue at position 267. 
1.3.2 - Cannabinoids 
More recently, GlyRs but not GABAARs have been identified as targets for 
cannabinoids.  At physiologically relevant concentrations, the endocannabinoids 
anandamide (AEA) and 2-arachidonylglycerol (2-AG) act directly on GlyRs in the 
hippocampus to modulate neuronal activity (Lozovaya et al., 2005).  Hejazi et al. (2006) 
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then demonstrated that AEA and 9-tetrahydrocannabinol (9-THC) are capable of 
potentiating glycine-evoked GlyR currents in neurons isolated from the rat ventral 
tegmental area (VTA) as well as 1 homomeric and  heteromeric GlyRs, activated by 
low (< 30M) concentrations of glycine, expressed in Xenopus laevis oocytes.  In both 
studies, these effects were shown to be completely independent of cannabinoid GPCR 
activity.  Xiong et al. (2011) used mutagenesis to identify a serine residue at position 296 
in 1 and an equivalent serine in 3 that is necessary for higher 9-THC sensitivity.  
They conferred similar sensitivity to the 2 subunit by mutating the corresponding 
alanine residue at position 303 to serine.  Performing the reverse mutation in 1 and 3 
significantly impaired modulation by 9-THC. 
1.3.3 - Neuroactive steroids 
 A number of neuroactive steroids are known to vary in their effects on different 
GlyR subunits.  Pregnenolone (PREG) potentiates 1 GlyR but has no effect on 2 or 
heteromeric receptors.  The synthetic neurosteroids, minaxolone, alphaxalone and 
Org20599 enhance recombinant 1 GlyR activity (Yevenes et al., 2011).  In contrast, 
pregnenolone sulfate (PREGS) and dehydroepiandrosterone (DHEAS) are inhibitory, 
with greater effects at 1 homomeric receptors than heteromeric or 2 homomeric GlyR, 
while progesterone shows 2-specific inhibition and acts at site distinct from that of 
PREGS (Betz and Laube, 2006; Webb and Lynch, 2007). 
1.3.4 - Ethanol 
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Excessive alcohol use is a global health problem and is estimated to be a 
contributing factor in ~3.8% of deaths, world-wide.  The costs associated with this 
account for more than 1% of the gross national product (GNP) in middle to high-income 
countries (Rehm et al., 2009).  In the United States, excessive alcohol consumption is the 
4th leading preventable causes of death, accounting for 1 in 10 deaths in working-age 
adults.  Between 2006 and 2010 an average of 87,798 people died from excessive alcohol 
use per year and 2.5 million years of potential life were lost (Stahre et al., 2014).  The 
economic burden of excessive drinking in the U.S. was $248 billion in 2010 alone, with 
approximately 77% of these costs attributed to binge drinking (Sacks et al., 2015). 
Some of the pharmacological effects of ethanol are believed to be due to its 
actions as a positive allosteric modulator of glycine and GABAA receptors.  Ethanol 
concentrations of 50mM or more consistently enhance GlyR currents elicited by taurine 
and sub-saturating concentrations of glycine (Webb and Lynch, 2007).  Two putative 
alcohol binding sites per subunit have been identified on the GlyR.  S267 and A288 in the 
transmembrane domain of 1 GlyR form part of a binding pocket that is critical for the 
potentiating actions of alcohols and anesthetics (McCracken et al., 2016; Mihic et al., 
1997).  Mutations in neighboring residues also have substantial effects on ethanol 
modulation of GlyRs.  Exchanging Q266 in TM2 with isoleucine abolished EtOH 
potentiation and significantly reduced agonist sensitivity.  M287L in TM3 also caused a 
significant reduction in EtOH potentiation (Borghese et al., 2012).  The consecutive 
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amino acids, I409, Y410 and K411 which are believed to form a hydrophilic cavity in 
TM4 are also critical determinants of EtOH modulation (Burgos et al., 2015). 
It has been proposed that the A52-containing Loop 2 region of the 1 GlyR forms 
a second binding site for ethanol (Naito et al., 2014; Perkins et al., 2012, 2008).  This 
confirms an earlier report by Mascia et al. (1996) showing that the potentiating effects of 
ethanol on glycine-evoked currents were attenuated in the murine spasmodic mutant, 
1A52S.  These studies, however, have focused on glycine-activated GlyR.  To our 
knowledge, no one has characterized the effects of taurine on GlyR Loop 2 mutants. 
Ethanol differentially modulates different GlyR subtypes, having substantially 
greater effects on 1 GlyRs compared to 2 and 3.  In the 2 subunit this difference 
has been mapped to a threonine residue in the Loop 2 domain.  In contrast, the 1 subunit 
contains an alanine at position 52.  Ethanol resistance in the 3 subunit is conferred by 
the 15-amino acid cassette in the IL discussed in greater detail above (Burgos et al., 
2015). 
Two conserved basic amino acid motifs in the GlyR intracellular loop, 
316RFRRK320 and 385KK386 are critical for a number of processes including membrane 
insertion, ion selectivity, nuclear import and interactions with G-protein G subunits.  
The latter function has been shown to enhance glycine-evoked currents at heterologously 
expressed GlyRs (Langlhofer and Villmann, 2016).  A number of studies have been 
published implicating the intracellular loop and its interactions with G-proteins in the 
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potentiating effects of ethanol (Castro et al., 2012; San Martin et al., 2012; Yevenes et al., 
2010).   
Yevenes et al. (2008) used alanine scanning experiments to identify amino acid 
sequences in the GlyR-IL that are critical for ethanol potentiation of 1 GlyRs.  They 
found that single and double alanine substitutions within two stretches of basic residues, 
316RFRRK320 and 385KK386, significantly attenuated ethanol potentiation of GlyR currents.  
San Martin (2012) and colleagues later blocked this interaction with a series of peptides 
based on residues 309-325 from the N-terminal portion of the IL in cultured spinal 
neuronscausing a concentration dependent inhibition of EtOH potentiation.  
K385A/K386A knock-in mice exhibited a 30% shorter loss of righting reflex (LORR), 
demonstrating that amino acid identity at these positions are also important for the effects 
of ethanol on motor control (Burgos et al., 2015). 
Single channel analysis of glycine-activated WT human 1 GlyRs expressed in 
oocytes revealed that EtOH increases durations of bursts and the number of openings per 
burst but had no effect on the percentage of time the channel spends in the open state 
within a burst or the likelihood of entering a given burst state (Welsh et al., 2009). The 
model constructed from these data suggest that EtOH increases glycine affinity for the 
receptor by antagonizing glycine unbinding.  Subsequent experiments of taurine-gated 
receptors led to the initial hypothesis that EtOH acted via a similar mechanism (Welsh et 
al., 2010).  Work by Kirson and colleagues (2012), however, showed that EtOH 
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potentiates GlyR currents elicited by maximally effective concentrations of taurine and 
must, therefore, also act to enhance taurine efficacy.  
The mesolimibic dopamine reward pathway, which originates in the ventral 
tegmental area (VTA) and projects to the nucleus accumbens (nAc), limbic system, and 
orbitofrontal cortex, mediates the reinforcing effects of drugs of abuse (Enoch, M., 2008).  
It is through this pathway that glycine receptors are believed to mediate drug-related 
behavior (Blednov et al., 2015; Jonsson et al., 2014; Li et al., 2012; Molander et. al, 
2005; Ye et. al, 2001).  There is increasing evidence for the role of GlyRs in the 
regulation of DA release in the nAc in response to alcohol.  Ye et al. (2001) identified 
alcohol-sensitive glycine receptors in dissociated VTA neurons from rats.  It was later 
shown that microdialysis of glycine into the nucleus accumbens of ethanol-preferring 
Wistar rats increased the levels of dopamine in this region (Ericson et al., 2006; Molander 
et al., 2005).  This same glycine treatment also caused a decrease in ethanol preference 
and consumption (Molander et al., 2005).  Male Wistar rats treated with ORG25935, an 
inhibitor of glycine transporter-1, also decreased their ethanol intake (Molander et al., 
2007).  Similarly, microinjection of glycine into the ventral tegmental area (VTA) 
decreased ethanol consumption in Long-Evans rats (Li et al., 2012). 
Acamprosate, a synthetic drug derived from homotaurine, is one of the few 
pharmacological interventions currently available for the treatment of alcohol addiction 
and is used to prevent relapse in abstinent alcoholics.  Chau et al. (2010) found that 
systemic treatment with acamprosate caused a decrease in voluntary alcohol intake in 
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medium- and high-alcohol-preferring rats, a behavior that was reversed by microinjection 
of strychnine into the nAc.  This suggests that the therapeutic effects of acamprosate may 
be mediated, at least in part, through GlyRs in the nAc and highlights their potential as a 
target for the treatment of addiction. 
1.3.5 - Zinc 
The divalent cation, zinc is ubiquitous in the CNS where it is crucial for proper 
brain development and function in animals and humans.  The majority of zinc in the brain 
is bound to proteins, leaving 10% as “free” chelatable zinc.  Some of this is packaged into 
presynaptic vesicles by members of the SLC30 superfamily of zinc transporters and can 
be released into the synapse in a calcium-dependent manner, along with neurotransmitters 
such as glycine and glutamate (Hirzel et al., 2006, Webb and Lynch, 2007; Trombley et 
al., 2011). 
Zinc is a biphasic modulator of GlyR function.  Concentrations <10 M potentiate 
GlyR currents while levels that surpass 10 M are inhibitory.  Tonic zinc concentrations 
have been estimated to be anywhere from 5-50 nM in human cerebral spinal fluid (CSF) 
(Fredrickson et al., 2006a) to as high as 200 nM (Hirzel et al., 2006).  Synaptic release, 
however, temporarily results in much higher concentrations, potentially in the inhibitory 
range, with earlier estimates ranging from <10 M to 100 M or more (Fredrickson et al., 
2006b; Qian and Noebels, 2005; Vogt et al., 2000).  More recently, Zhang et al. (2016a) 
used artificial synapses as a model to measure zinc concentrations following synaptic 
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release.  Their work suggests that synaptic zinc may reach levels of 1 M or more and are 
likely higher at glycinergic than glutamatergic synapses.  
The biphasic action of zinc on GlyRs is attributable to two types of binding sites 
on these receptors.  At low concentrations, zinc occupies high affinity binding sites on the 
outer surface of the N-terminal domain which causes potentiation of GlyR currents by 
enhancing agonist affinity for the receptor.  At higher concentrations, the high affinity 
binding sites are saturated and zinc also associates with lower affinity inhibitory binding 
sites on the inner side of the ECD, facing towards the vestibule (Burgos et al., 2016).  
Although both the 1 and 2 subunits have nanomolar affinity for zinc, 2 GlyR are 15x 
less sensitive to zinc potentiation.  It was determined that a single amino acid difference, 
D194 in 1 and E201 in 2, between the two subunits is responsible for this disparity.  
Mutating D194 to alanine abolished zinc potentiation of both glycine- and taurine-evoked 
currents, confirming that this residue is necessary for the enhancing effects of zinc 
(Miller et al., 2005).   
Additional residues have also been implicated in zinc potentiation.  The L274A 
mutation in the TM2-TM3 loop caused a reduction in glycine and taurine affinity while 
eliminating the potentiation of glycine- but not taurine-activated currents, suggesting that 
zinc has agonist-specific effects on GlyR function.  The intracellular M246A and D80A 
mutations were also reported to disrupt enhancement of glycine-evoked currents (Lynch 
et al., 1998), however mutations at D80 do not appear to affect zinc enhancement of 
taurine currents (Miller et al., 2005).  A more recent study, however, found no disruption 
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of zinc enhancement of glycine-activated currents in 1 D80A GlyRs expressed in 
oocytes and only partial attenuation of zinc effects at D80G (Cornelison et al., 2017).  
The 1 W170S is a gain-of-function, missense mutation in Loop F that causes an 
autosomal recessive form of human hyperekplexia and has been found to completely 
abolish zinc potentiation of glycine, taurine and -alanine currents, possibly by disrupting 
the nearby zinc binding site (Zhang et al., 2016b; Zhou et al., 2013).   
The zinc-coordinating actions of H107 and H109 at the inhibitory binding site in 
1 homomeric GlyRs was demonstrated by Harvey et al. (1999) who showed that 
deprotonating these residues at pH 5.4 was sufficient to disrupt zinc inhibition.  Their 
importance was further validated through mutagenesis.  A single histidine to alanine 
mutation at either H107 or H109 caused a significant decrease in zinc inhibition while the 
H107A/H109A double mutant was completely insensitive to the inhibitory effects of zinc 
(Harvey et al., 1999).   This also explains the lower sensitivity of 2 and 3 GlyRs to 
zinc inhibition as both subunits contain an asparagine residue at the site corresponding to 
H107 in the 1 subunit (Webb and Lynch, 2007).  A model based on the structure of 
AChBP showed that H107 and H109 are likely to be located near subunit interfaces 
(Laube, 2002).  It was later shown that these histidines form part of an intersubunit zinc 
binding site between H107 located on the (+) face and H109 and T133 on the (-) face 
which are believed to help stabilize the receptor in the closed state (Nevin et al., 2003).   
The actions of zinc on GlyRs are also important for glycinergic neurotransmission 
in vivo.  Homozygous D80A knock-in mice exhibited severe neuromotor defects, similar 
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to those found in the spasmodic, spastic and oscillator murine models of hyperekplexia, 
including an enhanced startle response, inducible tremors and impaired motor 
performance (Hirzel et al., 2006).  Zinc has also been shown to act synergistically with 
ethanol, but not pentanol or isoflurane, to further potentiate GlyR currents (McCracken et 
al., 2010).  Zinc sensitivity also seems to affect ethanol-related behavior.  McCracken et 
al. (2013) found that C57BL/6 mice expressing the D80A mutation in the 1 subunit of 
the GlyR showed a reduction in ethanol consumption and preference.   
1.4 - Channelopathies 
Glycine receptor dysfunction is implicated in multiple diseases.  Pre-synaptic 
3P185L GlyRs at glutamatergic terminals contribute to hyperexcitability and cognitive 
impairment in patients suffering from temporal lobe epilepsy (Langlhofer and Villman, 
2016).  There is also evidence that defects in the GlyR 2 subunit contribute to the 
pathology of Autism Spectrum Disorders (ASDs).  A rare human X-linked microdeletion 
of exons 8 and 9 encoding the TM3-4 loop in the Glra2 has been associated with autism.  
This variant was shown to cause a decrease in surface expression in vitro and severe 
defects in axon-branching in zebrafish.  Glra2 KO mice exhibited deficits in object 
recognition memory as well as impairment of long-term potentiation (LTP) in the pre-
frontal cortex (Langlhofer and Villman, 2016). 
1.4.1 - Hyperekplexia 
Disruption in glycinergic function is the major cause of the heritable neurological 
disorder, hyperekplexia.  Symptoms include an exaggerated startle response to 
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unexpected stimuli causing severe muscle rigidity, loss of postural control, tremors and 
apnoea.  This is most often treated with benzodiazepines, such as clonazepam, which 
increase GABergic activity (Lynch, 2004; Schaefer t al., 2013). 
The most common forms result from mutations in genes encoding GlyR subunits, 
however, some cases arise from mutations in SLC6A5, encoding the presynaptic glycine 
transporter 2 (GlyT2), and even more rarely, proteins responsible for anchoring synaptic 
GlyR such as gephyrin and collybistin (CB) (Langlhofer and Villmann, 2016).  Dominant 
hyperekplexia mutations tend to be located in the ion channel domain, causing defects in 
GlyR function.  Recessive mutations are more widely distributed and can affect surface 
expression, trafficking and receptor stability (Chung et al., 2010; Langlhofer and 
Villmann, 2016). 
Murine mutants exhibiting hyperekplexia-like phenotypes are common models of 
the human disorder.  The oscillator mutation is caused by a 7 base-pair deletion in exon 8 
of the 1 subunit that results in a premature stop codon.  Mice that are homozygous for 
this mutation lack 1-containing GlyR in the brainstem and spinal cord (Graham et al., 
2006).  Phenotypically, they start exhibiting symptoms at postnatal day 14 and die by 
postnatal day 21 (Langlhofer and Villmann, 2016).  The insertion of a LINE 1 
transposable element in the gene encoding the GlyR  subunit causes exon skipping 
which results in decreased transcription efficiency in spastic mice.  The 1 A52S 
substitution in Loop 2 of the ECD is found in the mouse spasmodic mutant.  These 
receptors show decreased agonist sensitivity similar to the 2 subunit (Graham et al., 
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2006).  This mutation is of particular interest as it has also been shown to have a 
significant effect on ethanol sensitivity (Mascia et al., 1996).   
1.4.2 - Inflammatory Pain Sensitization 
3-containing GlyRs are highly expressed in laminae I and II of the spinal cord 
dorsal horn where they act to regulate pain signaling (Betz and Laube, 2006).  
Heteromeric  receptors are particularly significant for inflammatory pain perception 
(Imlach et al., 2016).   The release of prostaglandin E2 (PGE2) increases PKA-dependent 
phosphorylation of S346 in the TM3-4 loop of the 3 subunit, causing a reduction in 
glycinergic signaling.  This results in decreased inhibition of nociceptive projection 
neurons, causing enhanced pain sensitization (Acuna et al., 2016; Lynch, 2009; 
Langlhofer and Villmann, 2016; Webb and Lynch, 2007).  Based on this mechanism, 3 
GlyRs present a promising target for pain management.   
Pharmacological agents targeting 3 receptors have already been shown to 
alleviate hyperalgesia in rodent models.  The analgesic effects of 9-THC have been 
demonstrated in WT, 2-/-, CB1-/- and CB2-/- but not 3-/- C57BL/6J mice, indicating that 
these effects are mediated by 3 GlyRs (Xiong et al., 2011).  Administration of 
cannabidiol and its derivative, dihydroxyl-CBD (DH-CBD), similarly reduced pain 
sensitization and perception in rats and specifically reversed PGE2-induced pain 
sensitization in mice (Xiong et al., 2011).  Acuna et al., 2016 later showed that 2,6-di-ert-
butylphenol (2,6-DTBP), a propofol derivative with M affinity for phosphorylated  
GlyRs, caused a significant reduction of induced hyperalgesia in mice.   
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Chapter 2: Materials and Methods 
 
 General experimental procedures and materials are described below.  Further 
information regarding specific experiments pertinent to each study can be found within 
the materials and methods section of the relevant chapter. 
2.1 - Buffers and Reagents 
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO) with the 
exception of tricaine which was purchased from Western Chemical, Inc. (Ferndale, WA).   
The following buffers were made using ultra-pure H2O.  pH was adjusted, as necessary, 
with NaOH or HCl. 
Barth’s saline (MBS): 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 10 mM HEPES, 
0.82 mM MgSO4•7H2O, 0.33 mM Ca(NO3)2, 0.91 mM CaCl2, pH 7.5  
Isolation Medium: 108 mM NaCl, 1 mM EDTA, 2 mM KCl, and 10 mM HEPES, pH 
7.5 
Incubation Medium: MBS with 2 mM sodium pyruvate, 0.5 mM theophylline, 10 U/ml 
penicillin, 10 mg/l streptomycin, and 50 mg/l gentamicin, pH 7.5 
Collagenase Solution: 83 mM NaCl, 2 mM MgCl2, and 5 mM HEPES, 0.5 mg/ml  
Sigma Type 1A collagenase, pH 7.5 
2.2 - Site-Directed Mutagenesis 
Point mutations were generated via site-directed mutagenesis using the 
QuickChange Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) 
and commercially engineered primers (Integrated DNA Technology, San Diego, CA) 
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using a wildtype (WT) glycine receptor cDNA template in a modified pBK-
cytomegalovirus vector containing a gene conferring resistance to the antibiotic 
kanamycin (Mihic et.al., 1997).  
Forward and reverse primers were combined with 5-50 ng of the GlyR template, 
reaction buffer, deoxynucleotide triphosphate mix and PfuTurbo DNA polymerase (2.5 
U/L) and run through the thermocycling protocol specified by the manufacturer.  Each 
reaction was then combined with 1 L of the Dpn I restriction enzyme (10 U/L) and 
incubated for 1 hour at 37C to digest the template DNA. 
The resulting plasmids were transformed into XL1-Blue Supercompetent E. coli 
cells (Agilent Technologies, Santa Clara, CA) and then grown on agar plates that 
contained 50 g/mL kanamycin to allow for selection of cells containing plasmid DNA.  
Individual colonies were then selected and grown overnight in LB broth in a shaker 
incubator set at 37C and 225-250 rpm.   
Plasmids were isolated using QIAprep® Spin Miniprep Kit according to the 
manufacturer’s instructions (Qiagen, Valencia, CA).  cDNA concentration and quality 
was assessed using a NanoDrop spectrophotometer (Thermo Scientific, Wilmington, 
DE).  Samples with an A260/280 of 1.8-2.0 and an A260/230 of > 1.8 were deemed suitable for 
injection into oocytes.  Mutations were verified through Sanger sequencing at the 
University of Texas at Austin DNA Sequencing Facility. 
2.3 - Oocyte Isolation and Injection 
37 
 
Female Xenopus laevis frogs were procured from Nasco (Fort Atkinson, WI) and 
housed at 19C on a 12-hour light/dark cycle.  Frogs were anesthetized for 10 minutes in a 
tricaine solution before performing partial ovariectomies under an approved IACUC 
animal protocol.  Portions of the ovary were removed through a 1 cm incision in the 
lower abdomen and stored in incubation medium until isolation.  The incision was closed 
with sutures and the frogs were allowed to recover for at least 3 hours in a separate 
container before being returned to their normal housing.  Each animal was allowed to 
recover for at least 4 weeks between surgeries. 
Stage V and VI oocytes were placed in a hypertonic isolation medium in order to 
make oocytes isolation easier.  Oocytes were isolated manually with forceps to remove 
the thecal and epithelial layers and temporarily stored in incubation medium that was 
sterilized by passage through a 0.22-m filter.  The follicular layer was removed by 
placing isolated oocytes in collagenase buffer for 10 minutes.  Following collagenase 
treatment, oocytes were placed in incubation medium where they remained throughout 
the injection process. 
 Oocytes were injected with 32.2 nL of human WT or mutant glycine receptor 
subunit cDNA at a concentration of 50 ng/L via the “blind” method of Colman (1984) 
using a micropipette (10-15 m tip size) attached to an electronic microdispenser.   
Oocytes were then placed, individually, in 96 well plates containing incubation medium 
and stored in the dark at room temperature prior to use. 
2.4 - Two-electrode Voltage-Clamp Electrophysiology 
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Oocytes expressed GlyRs within 24-48 hours.  All electrophysiology 
measurements were made 1-5 days following cDNA injection.  Oocytes were placed in a 
100 L bath with their animal poles facing upwards.  The animal pole of each cell was 
pierced with two high-resistance (0.5–10 MΩ) glass electrodes filled with 3 M KCl and 
voltage-clamped at -70 mV using an OC-725C oocyte clamp (Warner Instruments, 
Hamden, CT).  One electrode was used to constantly monitor the voltage across the 
membrane while the other was used to inject negative current into the cell to maintain the 
clamp.   
Oocytes were perfused with MBS at a rate of 2 mL/min using a Masterflex USA 
peristaltic pump (Cole Parmer Instrument Co., Vernon Hills, IL) through 18-gauge 
polyethylene tubing.  All solutions were prepared in standard MBS or MBS containing 
2.5 mM tricine.  Oocytes were preincubated with modulators for 30-60s prior to co-
application with agonist.  Agonist applications lasted 30s for submaximal concentrations 
and 15-30s for maximally-effective concentrations.  Washout periods ranged from 3-15 
minutes, depending on the concentration of agonist used. 
GlyR activation in this paradigm resulted in the outward flow of chloride ions.  
The current electrode was used to inject negative current into the cell, proportional to this 
chloride efflux, counteracting the resulting change in membrane potential.  The amount 
of current needed to maintain the voltage clamp was continuously monitored with a 
Powerlab 4/30 digitizer with LabChart version 7 software (ADInstruments, Bella Vista, 
NSW, Australia) and used later in data analysis. 
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Chapter 3: Allosteric modulation of Glycine Receptors Activated by 
Agonists Differing in Efficacy1 
3.1 – Introduction 
 The glycine receptor (GlyR) is a member of the Cys-loop family of ligand-gated 
ion channels.  It is the primary inhibitory receptor in the brainstem and spinal cord but 
also plays important roles in higher brain regions including the hippocampus, nucleus 
accumbens and prefrontal cortex (Baer et al 2009; Jonsson et al 2012, 2009; Lynch 
2004).  GlyRs are pentameric in structure with the 5 subunits arranged around a central 
anion-conducting channel.  Thus far, four alpha subunits and one beta subunit have been 
identified of which 1-3 and  are found in humans.  GlyRs express either as homomeric 
receptors composed solely of  subunits or as  heteromeric receptors with a 
stoichiometry of 2:3 (Betz et al 1993; Bowery et al 2006; Lynch 2004) or 
3:2(Grudzinska et al., 2005). 
 GlyR activity is affected by a large variety of allosteric modulators including zinc, 
alcohols, anesthetics and inhaled drugs of abuse (Beckstead et al 2000; Harvey et al 
1999; Mihic et al 1997), making it a promising clinical target for the treatment of alcohol 
and drug addiction (Tipps et al 2010).  Zinc is present endogenously at nanomolar 
concentrations known to enhance GlyR function.  Zinc exhibits biphasic actions at 
________________ 
1Portions of this chapter have previously been published in Brain Research. Farley, N-M. M., Mihic, S.J. 
2015. Allosteric modulation of the glycine receptor activated by agonists differing in efficacy. Brain Res 
1606, 95-101. Copyright © 2015 Elsevier Ltd. All rights reserved.  
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GlyRs, potentiating currents at concentrations <10 mM while higher concentrations 
produce inhibition (Harvey et al 1999, Laube et al 2000).   
Taurine is a partial agonist of the GlyR, with only 5% of the efficacy of glycine 
(Lape et al., 2008), and is believed to be an important GlyR agonist in a number of brain 
regions (Albrecht et al 2005; Mori et al 2002).  Previous research has largely focused on 
allosteric modulation at glycine-activated receptors.  Modulators shift glycine 
concentration-response curves either to the left or to the right but have no effects at 
maximally-effective glycine concentrations.  However, Kirson et al. (2012, 2013) showed 
that ethanol, volatile anesthetics, inhaled drugs of abuse and zinc are able to enhance 
currents elicited by maximally-effective concentrations of taurine, but not glycine.  This 
suggested that these modulators effect the probability of channel opening (Po), which 
would already be near maximum when a saturating concentration of glycine was tested.  
Most studies of allosteric modulation are performed using concentrations of agonists that 
are low on their concentration-response curves, since it is at these agonist concentrations 
that the greatest modulatory effects are seen.  I tested whether the effect of modulator-
induced increase in Po on taurine-activated GlyR would be seen when low concentrations 
of taurine were tested; i.e., did the magnitude of modulator enhancement differ when 
equi-effective concentrations of glycine and taurine were applied to GlyR?  
3.2 – Materials and Methods 
41 
 
3.2.1 - Two-electrode voltage-clamp electrophysiology 
 Oocyte isolation, injection and two-electrode voltage-clamp electrophysiology 
experiments were completed using the methods outlined in Chapter 2 with the following 
additions.  All solutions were prepared in one of the following: MBS, MBS + 100 nM 
zinc, MBS + 200 mM EtOH, or MBS + 2.5 M zinc with 2.5 mM tricine.  Drug 
applications lasted 30 s for submaximal glycine and taurine concentrations and 15 s when 
maximally-effective agonist concentrations were used. Washouts periods lasted 3-15 
minutes, as appropriate, for each agonist application.   
3.2.2 - Data Analysis 
Peak currents were measured and used in data analysis.  Currents observed in the 
presence of agonist were compared with currents elicited by co-application of agonist and 
modulator.  Experimental values are listed as the mean ± S.E.M.   Statistical significance 
was determined using t-tests, paired t-tests and Two-way ANOVAS and performed using 
SigmaPlot version 11.0 (Systat Software, San Jose, CA). 
3.3 – Results 
3.3.1 – Zinc enhancement of equivalent glycine and taurine currents at 1 wildtype 
glycine receptors 
Zinc was tested for its enhancing effects of 1 homomeric GlyR currents elicited 
by submaximal concentrations of glycine or taurine, two agonists which differ markedly 
in their efficacies.  Concentrations of each agonist were first identified that produced 
equal absolute currents, corresponding to 5 - 10% of the maximally-effective glycine  
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response (EC5-10 glycine).  In order to do so the EC5-10 concentration of glycine 
was first identified in each oocyte and then the concentration of taurine producing a 
similar current was determined.  Where that concentration of taurine fell on the taurine 
concentration- response curve was next determined, relative to a maximally-effective 
concentration of taurine (100 mM).   A concentration of 84 ± 4 M glycine had an EC 
value of 6.28 ± 0.70 relative to 10 mM glycine, while a concentration of 1.2 ± 0.2 mM 
taurine, producing currents of the same magnitude in each oocyte as glycine, had an EC 
value of 22.69 ± 3.98 relative to 100 mM taurine.  The concentrations of taurine used 
thus fell significantly higher on their concentration-response curves than the 
concentrations of glycine did on theirs [t(4) = 4.06, p < 0.005] (Fig. 3.1).  
 I next compared the enhancing effects of 100 nM zinc on currents produced by a 
low concentration of glycine with zinc effects on the same absolute currents produced by 
the partial agonist taurine.  In this experiment, zinc was co-applied with concentrations of 
glycine or taurine producing 5-10% of the maximally effective glycine response (EC5-10 
gly).  Zinc-potentiated currents were compared to those produced by agonist alone as 
shown in Figure 3.2A.  Co-application with zinc resulted in a significant enhancement of 
both glycine- and taurine-mediated currents [F(1,23) = 24.12, p < 0.001].   There was, 
however, no difference in the degree of zinc enhancement seen between glycine and 
taurine [F(1,23) = 1.19, p > 0.28]. 
 When data from individual oocytes were plotted (Fig. 3.2B), there was a large 
degree of variation in zinc enhancement seen.  Previous studies revealed that the buffers 
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used in our studies contain nanomolar levels of contaminating zinc, sufficient to affect 
GlyR function (Cornelison et al., 2014).  I hypothesized that the degree of variability 
within my data set might be attributable to variations in this amount of contaminating 
zinc between the different preparations of buffers used in this experiment.  In order to 
minimize the effects that variable background levels of zinc might have on my results, I 
repeated my previous experiment using a much higher concentration of zinc (2.5 M) 
applied with a fixed concentration (2.5 mM) of the zinc chelator, tricine.  This resulted in 
much lower inter-experiment variability in zinc enhancement but, again, no differences in 
zinc effects on glycine- vs. taurine-activated GlyR (Figs. 3.3A,B) [F(1,15) = 0.62, p > 
0.44].  
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Figure 3.1: Matching glycine and taurine currents differ in the respective EC 
values 
 
Low concentrations of glycine and taurine that elicit the same absolute currents 
correspond to very different effective concentrations on their respective concentration 
response curves.    The y-axis represents the percent maximal effect for each agonist 
respectively, relative to their maximal currents.  Data are shown as mean ± S.E.M. of 5 
oocytes. 
 
  
45 
 
3.3.2 – Concentration-dependent modulation of GlyR currents by zinc 
The goal of my next experiment was to determine how the percent enhancement 
of taurine-activated GlyR currents by zinc varied with taurine and glycine concentration.  
The average zinc percent potentiation as well as taurine EC value were plotted against 
taurine concentration (Fig. 3.4A).  A concentration of 2.5 M zinc (+ 2.5 mM tricine) 
enhanced taurine responses in a manner that was dependent on the concentration of 
taurine used [F(5,38) = 2.55, p < 0.05], with less enhancement seen at higher taurine 
concentrations.  However, it should be noted that, even at saturating taurine 
concentrations, zinc still had a potentiating effect.  When glycine was the agonist (Fig. 
3.4B) zinc again enhanced GlyR currents in a concentration-dependent manner [F(4,19) = 
16.29, p < 0.001], with less enhancement seen at higher glycine concentrations.  Zinc 
produced no enhancement at EC50 glycine concentrations and above, in contrast to the 
clear enhancement still seen at those taurine concentrations.   
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Figure 3.2: Zinc enhancement of equi-effective glycine and taurine currents 
 
Zinc potentiates currents induced by low concentrations of glycine and taurine eliciting 
the same absolute currents, to the same degree.  (A) Sample tracing showing that 
concentrations of glycine and taurine producing similar absolute currents result in similar 
degrees of enhancement by zinc.  (B) Summary of the potentiating effects of 5% maximal 
glycine- and taurine-evoked currents by 100 nM zinc.  (C) Graph showing the percentage 
of current enhancement of glycine and taurine currents by 100 nM zinc for individual 
oocytes plotted against their EC values relative to maximal glycine.  Data shown for 6 
oocytes. 
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3.3.3 – Ethanol enhancement of low glycine and taurine currents 
 In order to determine if the effects seen in my previous experiments were unique 
to zinc, I repeated that experimental protocol using another allosteric modulator, ethanol, 
in place of zinc.  Co-application of 200 mM ethanol had a significant potentiating effect 
on glycine- and taurine-mediated currents [F(1,19) = 123.22, p < 0.001].   However, there 
was no difference seen in the degree of potentiation between glycine and taurine [F(1,19) 
= 0.001, p > 0.97] (Fig. 3.5A), despite the significant difference [T(8) = 3.2, p <0.014] in 
their respective agonist EC values (Fig. 3.5B, inset).  All assays in this experiment were 
performed using a single preparation of MBS so that background contaminating levels of 
zinc would be constant throughout the experiment.  Data shown for individual oocytes 
(Fig. 3.5B) show less variability than seen previously when the concentration of 
contaminating zinc was not controlled (Fig. 3.2B). 
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Figure 3.3: Effects of tricine on zinc enhancement of low glycine and taurine 
currents 
 
Enhancement of GlyR function depends on the current produced rather than the agonist 
EC value.  (A) The degree of potentiation by 2.5 M zinc on currents elicited by low 
concentrations of glycine and taurine is the same for both agonists at concentrations 
producing the same absolute currents.  (B) Percent enhancement of glycine- and taurine-
mediated currents plotted against agonist EC value relative to a saturating concentration 
of glycine.  Applications were carried out in solutions containing 2.5mM tricine.   Data 
are shown as mean ± S.E.M. of 4 oocytes.  
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3.4 – Discussion 
 The GlyR is responsible for mediating much of the neuronal inhibition in the 
brainstem and spinal cord, although these receptors are also found in a number of higher 
brain regions (Baer et al 2009; Jonsson et al 2012, 2009; Lynch 2004).  A variety of 
structurally-diverse allosteric modulators are known to affect GlyR function including 
divalent cations, alcohols, anesthetics and numerous drugs of abuse (Beckstead et al 
2000; Harvey et al 1999; Kirson et al 2013, 2012; Mihic et al 1997).  Taurine is the 
second most abundant amino acid in the brain and may play a role in many brain regions 
as an agonist acting at the GlyR (Albrecht et al 2005, Mori et al 2002).  Although 
allosteric modulation of glycine-activated receptors has been quite extensively studied, 
not as much is known about modulation of GlyR activated by taurine.  
Depending on whether they are positive or negative allosteric modulators at the 
GlyR, compounds such as ethanol, inhalants and zinc either leftshift or rightshift glycine 
concentration-response curves, but have minimal to no effects when co-applied with 
saturating concentrations of glycine (Beckstead et al., 2000; Miller et al., 2005; Welsh et 
al., 2010).  The greatest percent enhancing or inhibiting effects of these agents are thus 
seen when low concentrations of agonists are tested and this is likely due to an 
enhancement of glycine affinity for its receptors.  However, these allosteric modulators 
have minimal effects when applied with saturating concentrations of glycine (Fig. 3.4B).  
In contrast, Kirson et al. (2012) showed marked enhancement by ethanol, volatile 
anesthetics and inhaled drugs of abuse when co-applied with maximally-effective 
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concentrations of taurine.  The same phenomenon was later shown using 100 nM zinc 
(Kirson et al. 2013).  The effects of these agents at saturating concentrations of taurine 
cannot be due to their enhancement of taurine binding but must instead be due to their 
increasing the probability of channel opening (Po) subsequent to binding.   In contrast, 
since a saturating concentration of glycine produces a Po of approximately 0.95 (Lape et 
al., 2008), there is little room for enhancement of Po by modulators.  I tested whether the 
enhancing effect of zinc on taurine-activated GlyR would only occur through its effects 
on Po.  If so, then it seems unlikely that the zinc percent potentiation should depend on 
the taurine concentration tested; i.e., I would have expected a flat line in Fig. 3.4A.  
Instead I observed progressively greater enhancement as the taurine concentration 
decreased, until it reached approximately 200% at low taurine concentrations (Fig. 3.4A).  
This was markedly greater than the ~120% maximal enhancement seen when low 
concentrations of glycine were tested (Fig. 3.4B).  These studies did not, however, 
address allosteric enhancement of currents induced by low concentrations of agonist.  I 
sought to determine whether the enhancement by allosteric modulators seen at GlyRs 
activated by low concentrations of taurine is also due solely to increasing Po. 
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Figure 3.4: Concentration dependence of zinc effects on glycine and taurine  
currents  
 
Zinc enhances taurine- and glycine-mediated GlyR currents in a concentration-dependent 
manner.  (A) Taurine and (B) glycine concentration response curves and percent 
enhancement produced by 2.5 M zinc at each concentration.  (C) Zinc enhancement of 
GlyR function plotted against the respective glycine and taurine EC values.  All tests 
were carried out in solutions containing 2.5mM tricine. 
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For this purpose, I began my work by comparing how 100 nM zinc affected the 
GlyRs response to low concentrations of glycine vs. taurine.  In order to properly 
compare effects on receptor activity, I determined the concentrations of glycine and 
taurine that produced the same absolute current.  These concentrations corresponded to 
drastically different relative EC values for these agonists (Fig. 3.1).  I expected that the 
degree of zinc potentiation would be lower for taurine than glycine as I was much higher 
on the taurine concentration response curve.  My data, however, showed the same degree 
of enhancement for both agonists (Fig. 3.2A), indicating that zinc potentiation was 
dependent on the amount of current produced.  
Closer examination of the individual data points, revealed a great deal of 
variation.  A recent study, however, had shown that there are nanomolar concentrations 
of contaminating zinc present in our buffers which would affect GlyR function.  
Furthermore, these concentrations vary from one of solution to the next (Cornelison et al., 
2014).   Based on this information, I thought it possible that the variation among my 
individual data points (Fig. 3.2B) may be due to varying levels of contaminating zinc 
present in different batches of my solutions.  In this case, depending on the degree of 
variation in zinc contamination, my results might not have been reliable. 
In order to mitigate this problem and increase accuracy, I repeated my 
experiments using a higher concentration of zinc (2.5 M) and added 2.5 mM tricine to 
all of my buffers to chelate out background levels of zinc.  My results showed no 
difference in the degree of potentiation of glycine- and taurine-evoked currents (Fig. 3.3), 
53 
 
which was consistent with the findings of my previous experiment (Fig. 3.2A).  I saw 
similar results when with 200 mM ethanol (Fig. 3.5), indicating that the mechanism of 
allosteric enhancement of taurine currents is not unique to zinc. 
Zinc was able to enhance currents elicited by maximally-effective concentrations 
of taurine by increasing Po (Kirson et al 2013).  To determine if potentiation of taurine 
currents was solely attributable to increasing Po I measured the percent enhancement of 
taurine-activated currents across a wide range of taurine concentrations.  If Po were the 
only determining factor, one would expect the percent current enhancement to be the 
same for all concentrations of taurine.  My data showed that current enhancement at low 
concentrations of taurine was significantly higher than at high concentrations (Fig. 3.4).  
This suggests that allosteric modulators such as zinc also affect taurine affinity at these 
lower concentrations, by enhancing taurine binding rates or antagonizing taurine 
unbinding.  
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Figure 3.5: Enhancement of matching glycine and taurine currents by 200 mM 
ethanol. 
 
At low agonist concentrations, ethanol potentiation of glycine- and taurine-evoked 
currents equal to 5-10% of maximal current equivalent and dependent on the absolute 
current produced.  (A) Summary of the potentiating effects of 5-10% maximal glycine- 
and taurine-evoked currents by 200 mM EtOH.  (B) Graph showing the percentage of 
current enhancement of glycine and taurine currents by 200 mM ethanol for individual 
oocytes plotted against their EC values relative to maximal glycine.  Data are shown for 5 
oocytes.  
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Chapter 4: Mutation-induced changes in agonist efficacy alter allosteric  
modulation of the glycine receptor 
4.1 – Introduction 
The glycine receptor (GlyR) is the primary mediator of inhibitory 
neurotransmission in the brainstem and spinal cord and has also been found in higher 
brain regions such as the hippocampus, prefrontal cortex and nucleus accumbens (Baer et 
al 2009; Jonsson et al 2012, 2009; Lynch 2004).  Four alpha and one beta subunit have 
been discovered of which, all but 4 can be found in humans.  GlyRs are expressed 
endogenously as homopentamers composed solely of alpha subunits or as 
heteropentamers with a stoichiometry of  (Betz et al 1993; Bowery et al 2006; 
Lynch 2004) or 3  (Grudzinska et al., 2005) arranged around a central anion-
conducting channel.  Taurine is a partial agonist exhibiting approximately 5% the 
efficacy of glycine at WT (WT) GlyR (Lape et al. 2008).  Although glycine is the 
prototypical agonist in vivo, evidence exists supporting the role of taurine as an important 
GlyR agonist in numerous brain regions (Albrecht and Schousboe 2005).  This is 
supported by the work of Mori et al. (2002) who showed that a taurine uptake inhibitor 
induced a strychnine-sensitive chloride current in hippocampal organotypic slice cultures.   
GlyR function is modulated by a variety of endogenous compounds such as zinc, 
endocannabinoids and neuroactive steroids (Laube et al., 2000; Lynch, 2004; Yevenes, 
et.al., 2011) as well as numerous addictive drugs including alcohols, anesthetics and 
inhalants (Beckstead et al., 2000; Harvey et al., 1999; Kirson et al., 2013, 2012; Mascia et 
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al. 1996; Mihic et al., 1997).  The divalent cation zinc is present both in vivo and as a 
contaminant in buffers at concentrations sufficient to modulate GlyR function 
(Frederickson et al, 2006a, 2006b; Hirzel et al, 2006; Cornelison and Mihic, 2014).  This 
biphasic modulator interacts with some other modulators, such as ethanol, to affect 
receptor activity (Bloomenthal et. al., 1994; Cornelison et al., 2017; McCracken et al., 
2013, 2010).  The tryptophan to serine mutation at residue 170 (W170S) of the 1 GlyR 
leads to one form of human hyperekplexia (Zhou et al., 2013).  This mutation yields 
receptors insensitive to enhancing concentrations of zinc (<10uM), thus allowing for the 
study of allosteric modulation of GlyR without the confounding effects of zinc 
enhancement. 
GlyRs have been implicated in alcohol-related behaviors.  McCracken et al. 
(2013) found that C57BL/6 mice expressing the D80A mutation in the 1 subunit of the 
GlyR showed a reduction in ethanol consumption and preference.  This is consistent with 
earlier studies showing that the GlyR mediates behavioral actions of drugs of abuse (Li et 
al., 2012; Molander et. al, 2005; Ye et. al, 2001) and further highlights its potential as a 
target for the treatment of addiction.  Two putative alcohol binding sites have been 
identified on the GlyR.  S267 and A288 in the transmembrane domain of 1 GlyR form 
part of a binding pocket that is critical for the potentiating actions of alcohols and 
anesthetics (McCracken et al., 2016; Mihic et al., 1997) The potentiating effects of 
ethanol on glycine-evoked currents were also attenuated in the murine 1 A52S 
spasmodic mutant (Mascia et al., 1996).  It has since been proposed that the A52-
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containing Loop 2 region of the 1 GlyR forms a second binding site for ethanol (Naito 
et al., 2014; Perkins et al., 2008, 2012).  All of these studies, however, have focused on 
glycine-activated GlyR but, to our knowledge, no one has characterized the effects of 
taurine on GlyR Loop 2 mutants. 
In earlier experiments, I found that the degree of potentiation of WT homomeric 
1 GlyR currents produced by ethanol is greater, across all agonist concentrations, for 
taurine than glycine.  I believe that this effect may be due to taurine having a lower 
efficacy than glycine.  I hypothesized that mutation-induced changes in allosteric 
modulation may be due to changes in agonist efficacy produced by these mutations.  To 
explore this possibility, I chose to examine GlyR mutants that displayed altered responses 
to known GlyR modulators. 
 Previous studies by (Wallner et al. 2006, 2003) claimed that GABAA receptors 
containing the  subunit are sensitive to very low concentrations of ethanol.  Based on 
this information, Naito et al. (2015, 2014) generated a series of mutations in the Loop 2 
of the glycine receptor based on the corresponding sequence in the GABAA  subunit that 
they named, Ultra-Sensitive to Ethanol Receptors (USERs).  They reported astonishingly 
low ethanol sensitivities at these receptors, making them attractive models with which to 
test our theory.   
I attempted to characterize the ethanol sensitivity of USERs 1-3 as well as a series 
of partial USER mutants generated in the lab, that contained some, but not all, of the 
mutated residues found in USER3, with the hope of identifying the contributions of 
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specific residues to this phenotype.  I also examined the actions of taurine and ethanol on 
A52S and W170S mutant receptors, which display decreased and increased taurine 
efficacy, respectively, allowing me to further explore the link between agonist efficacy 
and allosteric modulation. 
4.2 – Materials and Methods 
4.2.1 - Generation of Point Mutations 
 The 1 A52S and W170S point mutations were generated via site-directed 
mutagenesis using the methods described in Chapter 2.  The USER mutants were a gift 
from the Davies lab at the University of Southern California (Los Angeles, CA). 
4.2.2 – Two-electrode voltage-clamp electrophysiology 
Oocyte isolation, injection and two-electrode voltage-clamp electrophysiology 
experiments were completed using the methods outlined in Chapter 2 with the following 
modifications.   
Oocytes were preincubated with modulators for 30-60s prior to co-application 
with either glycine or taurine.  Agonist applications lasted 30s for submaximally-effective 
agonist concentrations and 15-30s for maximally-effective concentrations of agonists.  
Washout periods ranged from 3-15 minutes, depending on the concentration of agonist 
used, to allow for receptor resensitization.  Data were acquired using a Powerlab 4/30 
digitizer with LabChart version 7 software (ADInstruments, Bella Vista, NSW, Australia) 
and stored on a computer hard drive for later analysis.   
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4.2.3 - Data Analysis 
Peak currents observed in the presence of agonist were compared with currents 
produced by agonist with modulator.  Values are listed as the mean ± S.E.M.  t-tests, 
paired t-tests, 2-way and 3-way ANOVAs were used to determine statistical significance, 
as indicated.  Statistical testing was performed using SigmaPlot version 11.0 (Systat 
Software, San Jose, CA). 
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Fig 4.1 - Sequence alignment of the 1 GlyR Loop 2 domain of wildtype, USER and 
partial USER mutants 
 
Sequence alignment of wildtype, USER and partial USER mutations in Loop2 of the 
extracellular domain.  Mutated residues are shown in red. 
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4.3 – Results 
4.3.1 – Effects of Loop 2 mutations on ethanol modulation of 1 glycine receptors 
Perkins et al. (2009) and Naito et al. (2014) reported that replacing a region of 
loop 2 of the 1 GlyR and 2 GABAAR with the equivalent amino acids found in the 
GABAAR  subunit substantially increased ethanol sensitivity at these USER (ultra-low 
sensitivity to ethanol receptor) mutants.  USERS 1, 2 and 3 contain 6, 5, and 4 mutations 
in Loop 2, respectively (Figure 4.1).  I generated a series of mutants based off of the 
USER3 sequence, shown in (Figure 4.1) to determine if a subset of these residues was 
responsible for the enhanced ethanol sensitivity reported in the literature. Unfortunately, 
none of my mutants resembled USER in their responses to ethanol (Data not shown).   
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Fig 4.2 - Effects of low concentrations of ethanol on EC2 glycine-activated USER vs. 
wildtype GlyRs 
 
Summary graphs showing the degree of potentiation by 500 M (grey bars) or 1 mM 
(black bars) ethanol of currents produced by low (EC2) glycine.   (A-C) There is no 
significant difference in the degree of enhancement between wildtype and USER glycine 
receptors at either concentration.  Data are shown as mean ± S.E.M. of 6-9 oocytes. 
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I next attempted to confirm the original USER data by testing the effects of 500 
M and 1 mM EtOH on EC2 glycine-activated receptors.  As shown in Figure 4.2, none 
of the USER mutants differed significantly from WT in their response to low 
concentrations of ethanol.  Despite my failure to reaffirm the nature of the purported 
ultra-sensitive mutants, I wondered how they would respond to taurine.  I measured the 
effects of maximally-effective concentrations of taurine and glycine at the three USER 
mutants.  I found no significant difference in the relative efficacy of taurine at USER1 
[t(12) = 1.01, p > 0.33] and USER3 [t(11) = 0.17, p > 0.86] but saw a reduction in 
average taurine efficacy at USER2 (Figure 4.3).  Next, I coapplied 200 mM EtOH with 
max taurine to determine if there was a change in ethanol modulation.  Again, USERs 1 
[t(12) = 1.71, p > 0.11] and 3 [t(11) = 0.55, p > 0.59] did not differ significantly from 
WT, but USER2 displayed a marked increase in EtOH potentiation of currents elicited by 
maximally-effective taurine concentrations [t(18) = 3.18, p < 0.006] (Figure 4.4).  
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Fig 4.3 - Relative efficacy of taurine currents at wildtype and USER 1 glycine 
receptors 
 
Graphs showing the average peak currents produced by maximally effective 
concentrations of taurine relative to glycine at USER and WT GlyRs.  The relative 
efficacy of taurine at (A) USER1 and (B) USER3 GlyRs does not differ significantly 
from WT.  (B) Taurine has decreased efficacy at USER2.  All data are normalized to 
currents produced by 10mM glycine.  Data are shown as mean ± S.E.M. of 5-12 oocytes. 
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Fig 4.4 - Ethanol potentiation of max taurine currents at USERs 
 
Summary graphs showing the percent potentiation of saturating taurine currents after co-
application with 200 mM ethanol.  There is no significant difference in the degree of 
ethanol potentiation of maximally effective taurine currents between (A) USER1 or (C) 
USER3 and WT.  (B) Ethanol potentiation of saturating taurine currents is significantly 
increased at USER2 GlyRs.  Data are shown as mean ± S.E.M. of 5-12 oocytes. 
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4.3.2 – Characterization of taurine-activated 1 A52S GlyR enhancement by zinc  
and ethanol 
The only difference between GlyR USER1 and USER2 is the A52S mutation 
found in USER1.  Mascia et al. (1996) previously found that the 1 A52S mutation 
resulted in a decreased sensitivity to glycine and reduced potentiation of glycine-evoked 
currents by ethanol.  These data suggest that the residue at position 52 has an important 
role mediating the effects of ethanol at glycine-activated GlyRs, however, the effects of 
the A52S mutation on taurine-evoked currents was still unknown. 
I characterized the actions of taurine at 1 glycine receptors compared to WT.    
Concentration response curves for both glycine and taurine were constructed.  The 
agonist concentration-response curve was right-shifted in the mutant when glycine was 
the agonist, which agrees with the findings of Mascia et al. (1996).  A two-way ANOVA 
showed a significant effect of receptor when activated by glycine [F(1,95) = 6.46, p < 
0.014].  However, no significant effect of receptor was seen between WT and A52S in 
response to taurine [F(1,89) = 0.72, p > 0.39] (Fig. 4.5). 
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Fig 4.5 - Agonist concentration response curves for wildtype and A52S 1 glycine 
receptors 
 
Concentration response curves for glycine (circles) and taurine (triangles) in Xenopus 
laevis oocytes expressing either homomeric 1A52S or WT GlyRs.  Values are normalized 
to the maximal currents elicited by each agonist.  The A52S mutant is less sensitive to 
glycine than WT.  There is no significant effect of receptor when taurine is the agonist.  
Data are shown as mean ± S.E.M. of 4-9 oocytes. 
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The enhancing effects of ethanol on currents produced by submaximal 
concentrations of glycine and taurine were next tested in WT and A52S GlyR.  In each 
oocyte, concentrations of glycine and taurine were determined that produced currents 
corresponding to 5-10% of the maximal response (EC5-10) to each agonist.  These were 
then co-applied with 50, 100 or 200 mM ethanol.  Co-application with ethanol increased 
the degree of potentiation of taurine-mediated currents in the A52S mutant by ethanol 
when compared to WT [F(1,65) = 5.692, p = 0.020] (Fig 4.6A).  However, contrary to 
what was reported by Mascia et al. (1996), no significant difference in the degree of 
ethanol potentiation of currents produced by glycine was seen [F(1,66) = 1.18, p = 0.28] 
(Fig. 4.6B).   
Taurine efficacy relative to glycine was determined by comparing current 
amplitudes produced by saturating concentrations of both agonists.  Figure 4.7A shows 
that 100 mM taurine has significantly lower efficacy at A52S than WT 1 GlyR, relative 
to the currents elicited by 10 mM glycine in those receptors [t(8) = 3.98, p < 0.005].   
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Fig 4.6 - Ethanol modulation of low glycine- and taurine-evoked currents at 
wildtype and A52S 
 
Effects of enhancing concentrations of ethanol on WT and A52S glycine receptors 
activated by EC5-10 glycine or taurine.  (A) Ethanol enhances currents elicited by the 
partial agonist taurine to a greater degree in 1A52S mutant receptors than WT.  (B) There 
was no difference in the degree of ethanol enhancement of glycine-evoked currents 
between WT and A52S.  Data are presented as mean ± S.E.M. for 7-10 oocytes. 
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Previously I hypothesized that the greater degree of allosteric modulation seen in 
GlyRs that are activated by taurine compared to glycine may be related to the 
significantly lower efficacy of taurine at WT receptors (Farley and Mihic, 2015).  
Maximally-effective taurine-activated currents are potentiated by ethanol and zinc which 
must be due to an increase in the probability of channel opening (Po).   
Since taurine has reduced efficacy at A52S 1 GlyR I tested whether there was a 
corresponding increase in the degree of ethanol potentiation.  Peak currents elicited by 
100 mM taurine were compared to those produced by co-application of taurine with 
ethanol.  Ethanol, at a concentration of 200 mM enhanced taurine currents to a greater 
extent in A52S than in WT 1 GlyR [t(8) = 2.73, p < 0.03] (Fig. 4.7B). 
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Fig 4.7 - Relative efficacy of taurine at wildtype and A52S GlyRs 
 
Peak currents produced by saturating concentrations of glycine and taurine.  (A) Taurine 
has lower efficacy relative to glycine at 1A52S vs. WT GlyRs.  (B) Enhancement of 
maximally effective taurine currents by 200mM ethanol is greater at A52S than WT.  All 
data are normalized to currents produced by saturating glycine.   Data are shown as mean 
± S.E.M. of 4-6 oocytes. 
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Since GlyR function is affected by nanomolar, contaminating levels of zinc found 
in perfusion buffers (Cornelison and Mihic, 2014), some of the differences observed 
between WT and A52S GlyR might be due, in part, to differences in zinc sensitivity 
between these receptors.  To determine if this was the case, the degree of zinc modulation 
between WT and mutant A52S GlyR was compared at low and maximally-effective 
concentrations of taurine (Figure 4.8).  First, the concentration of taurine that produced 
EC4-10 currents was determined and then the degree of modulation produced by co-
application of taurine with 0.1 and 1 M zinc, concentrations of which potentiate currents 
at WT receptors (Figure 4.8).  Similarly, I measured the effects of 100 M zinc, which 
inhibits GlyR currents (Harvey et al., 1999; Laube et al. 2000).   I then repeated these 
experiments using 100 mM taurine (Figure 4.8).  A two-way ANOVA showed no 
significant effect of receptor at either EC4-10 [F(1,40) = 1.51, p > 0.22] or saturating 
concentrations of taurine [F(1,35) = 0.92, p > 0.34] (Fig 4.8). 
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Fig 4.8 - Effects of zinc at taurine-activated wildtype and A52S receptors 
 
Effects of 100 nM, 1 M and 100 M ZnCl2 on WT and 1A52S GlyRs activated by low 
(triangles) and high (circles) concentrations of taurine.  Zinc modulates currents elicited 
by EC4-10 and maximally effective concentrations of taurine to the same extent in A52S 
and WT receptors.  Data are shown as mean ± S.E.M. of 5-8 oocytes. 
. 
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4.3.3 – Effects of zinc and ethanol on taurine-evoked currents at W170S glycine 
receptors 
Cornelison et al. (2017) demonstrated that the W170S 1 GlyR human 
hyperekplexia mutant, which is insensitive to zinc potentiation, can be used to study 
ethanol modulation of glycine-activated GlyRs without the added complication of zinc 
modulation.  I characterized the effects of taurine at this receptor.  Taurine concentration-
response curves for W170S and WT GlyR were first generated (Figure 4.9).  Although 
the W170S curve appears slightly right-shifted, a two-way ANOVA showed no 
significant effect of receptor [F(1,64) = 0.33, p > 0.56].  Interestingly, as seen in Figure 
4.10A, taurine has much higher efficacy at the W170S 1 GlyR compared to WT 
receptors. 
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Fig 4.9 - Taurine concentration response curves for wildtype and W170S 1 glycine 
receptors 
 
Concentration response curves for whole-cell taurine currents in oocytes expressing 
homomeric 1W170S or WT GlyRs.  There is no significant effect of receptor between 
W170S and WT.  Values are expressed as a percentage of the maximal taurine current in 
each oocyte.  Data are shown as mean ± S.E.M. of 3-5 oocytes. 
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Due to its high efficacy, the probability of channel opening for WT GlyR at 
saturating glycine concentrations is near 1.  As a result, ethanol has minimal effects at 
receptors activated by high concentrations of glycine (Kirson et al., 2012).  Since taurine 
has much higher efficacy relative to glycine at W170S GlyR, I postulated that maximally-
effective taurine currents would display a similar absence of ethanol potentiation.  Upon 
comparing the effects of 200mM ethanol on currents produced by 100 mM taurine, 
significantly greater effects were found in WT than W170S 1 GlyR [t(14) = 3.46, p < 
0.005] (Figure 4.10B). 
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Fig 4.10 - Relative efficacy of taurine at wildtype and W170S GlyRs 
 
Magnitude of 100 mM taurine currents and effects of 200mM ethanol on taurine-
activated 1W170S and WT glycine receptors.  (A) The W170S mutation drastically 
increases taurine efficacy and (B) abolishes ethanol potentiation of currents produced by 
saturating concentrations of taurine.  Data are shown as mean ± S.E.M. of 8-9 oocytes. 
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W170S GlyRs exhibit a lower degree of ethanol enhancement of glycine currents 
when tested in standard MBS buffer, which contains low nanomolar concentrations of 
contaminating zinc.  This difference, however, was eliminated in the presence of the zinc 
chelator, tricine (Cornelison et al. 2017).  I performed similar experiments to determine 
whether the same phenomenon occurs when taurine is the agonist.  I began by measuring 
the enhancement of EC5-10 taurine currents by ethanol in our normal MBS buffer.  The 
degree of potentiation produced by 50 mM ethanol was significantly lower in W170S 
than WT GlyR [t(13) = 2.95, p < 0.015] (Fig. 4.12A).  I then repeated these experiments 
using MBS that contained 2.5 mM tricine.  As seen with glycine previously (Cornelison 
et al., 2017), there was no statistically significant difference in ethanol modulation of 
currents elicited by low taurine concentrations between W170S and WT at either 50 or 
200 mM ethanol concentration (Fig. 4.12B).     
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Fig 4.11 - Effects of ethanol and tricine on low taurine-evoked currents at W170S 
and wildtype receptors 
 
Effects of zinc chelation on ethanol enhancement of W170S and WT GlyRs.  (A) 50 mM 
ethanol enhancement of taurine currents at W170S was much lower than WT in the 
presence of low concentrations of contaminating zinc.  Data are shown as mean ± S.E.M. 
of 7-8 oocytes.  (B) There was no significant difference in the degree of ethanol 
modulation between WT and W170S in the presence of 2.5mM tricine.  Data shown as 
mean ± S.E.M. of 5 oocytes. 
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4.4 – Discussion 
A large number of allosteric modulators, such as divalent cations, neurosteroids, 
endocannabinoids, alcohols and anesthetics influence GlyR activity (Beckstead et al., 
2000; Harvey et al., 1999; Kirson et al., 2013, 2012; Mascia et al. 1996; Mihic et al., 
1997, Yevenes, et al., 2011).  GlyRs are believed to play a role in the development of 
alcohol addiction and mediate some of the behavioral effects of ethanol (Li et al., 2012; 
McCracken et al, 2013; Molander et. al, 2005, 2007; Ye et. al, 2001).  Thus far, most 
GlyR research has focused on receptors activated by glycine, however, the lower efficacy 
compound taurine is also believed to be an important GlyR agonist in vivo (Albrecht and 
Schousboe, 2005; Mori et al., 2002).  
 Positive allosteric modulators like ethanol have minimal effects at saturating 
concentrations of high-efficacy agonists, like glycine, because the probability of channel 
opening (P) is already close to 1 when the agonist is applied alone.  By comparison, the 
Po for WT 1 homomeric GlyRs activated by maximally-effective concentrations of 
taurine is only ~0.5.  The abilities of modulators to increase the Po of GlyRs gated by 
high concentrations of low efficacy agonists explains the findings of Kirson et al. (2012, 
2013) who observed significant enhancement of saturating taurine- but not glycine-
evoked currents by isoflurane and zinc.   I obtained similar results with ethanol and zinc 
at WT 1 GlyRs (Farley and Mihic, 2015) which raised the question of whether a 
relationship exists between the efficacy of an agonist and the degree of modulation 
observed when it is applied at a saturating concentration.  Based on my previous results, I 
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hypothesized that the degree of allosteric modulation dependents on agonist efficacy, and 
that mutations that decrease agonist efficacy would show a corresponding increase in the 
magnitude of modulation.  Similarly, if an agonist were to have higher efficacy at a 
particular mutant, this would lead to a decrease in the degree of modulation. 
Loop 2 of the 1 subunit is located at the interface between the extracellular and 
transmembrane domains and has been hypothesized to form part of a second alcohol 
binding pocket (Crawford et al., 2007; Naito et al., 2014; Perkins et al., 2008, 2009, 
2012).  Perkins et al. (2009, 2012) generated a series of mutants in loop 2 of the 1 GlyR 
by mutating non-conserved residues to those present in the GABAA  subunit (Fig. 4.1).  
They reported a significant decrease in the threshold ethanol sensitivity of these USER 
(ultra-low sensitivity to ethanol) mutants when activated by glycine.  USER3 contains 
fewer mutations than USERs 1 and 2 with only 4 residues that differ from WT.  I tested a 
series of mutants that contained 1-3 of the mutations found in USER3 to see if these were 
sufficient to confer enhanced ethanol sensitivity (Figure 4.1).  The A52S mutation is 
known to decrease ethanol potentiation of 1 GlyR currents and was therefore excluded.  
Unfortunately, none of my partial USER mutants displayed an enhanced response to 
ethanol when compared to WT (data not shown). 
Troubled by these results, I attempted to verify the ultra-sensitive phenotype of 
the USER mutants by repeating some of the original experiments, to the best of my 
ability.  I tested the effects of two low ethanol concentrations that were reported to have 
particularly robust effects on currents produced by EC2 glycine (Naito et al. 2014).  As 
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seen in Figure 4.2, however, I was unable to substantiate these claims.  In my hands, none 
of these USER mutants differed from WT in their response to 500 M and 1 mM EtOH.   
In spite of these findings, I thought it prudent to characterize the effects of taurine 
at these receptors.  I tested the effects of maximally effective concentrations of taurine 
and glycine on oocytes expressing USERs 1-3 or WT GlyRs as well as the effects of 
200mM EtOH on these receptors when activated by saturating taurine.  I found no 
significant difference between USER1 or USER3 and WT in either experiment, however, 
USER2 showed a striking decrease in response to taurine relative to glycine, indicating 
that taurine has reduced efficacy (Figure 4.43).  Furthermore, ethanol potentiation of max 
taurine currents in USER2 was significantly higher than the degree of potentiation 
observed in WT (Figure 4.4).  Given that the only difference between USERs 1 and 2 is 
A52S, these data reinforce the idea that the residue at position 52 of the 1 subunit plays 
an important role in determining how glycine receptors respond to ethanol when activated 
by taurine.  It also provides further evidence of an inverse relationship between agonist 
efficacy and the degree of allosteric modulation at glycine receptors.  However, one 
curious finding is that the A52S mutation made in WT receptors decreases taurine 
relative efficacy while the same mutation in USER2 to make USER 1 increases taurine’s 
efficacy relative to glycine. 
Mascia et al. (1996) demonstrated that the murine spasmodic mutant A52S 
residue, located in Loop 2, decreases ethanol sensitivity in 1 homomeric GlyRs 
activated by glycine.  However, allosteric modulation of A52S GlyRs when gated by 
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taurine had not yet been investigated.  I expanded on the work of Mascia and colleagues 
to better characterize the actions of glycine, taurine and ethanol at these receptors.   
In my hands, the A52S mutant showed a small decrease in glycine sensitivity 
relative to WT GlyR, as evidenced by the right-ward shift in the concentration response 
curve for A52S (Figure 4.5).  This is in agreement with Mascia et al. (1996).  The taurine 
concentration-response curves for the A52S 1 GlyR also appeared to be right-shifted to 
a similar degree compared to WT, but this was not statistically significant.  I next 
compared the degree of ethanol potentiation of currents elicited by EC5-10 glycine and 
taurine at A52S and WT GlyR and found that the degree of potentiation by ethanol was 
significantly greater at A52S GlyR than WT when taurine was the agonist (Figure 4.6A).  
I saw no difference between A52S and WT when activated by glycine (Figure 4.6B), 
however, which contradicts earlier work that showed a decrease in glycine-evoked 
current enhancement in A52S relative to WT (Mascia et al., 1996).   
 It is possible that this discrepancy is due to differences in background levels of 
zinc in my experiments, compared to those of Mascia et al. (1996).  Zinc contaminates 
reagents and buffers at low nanomolar concentrations, high enough to significantly 
enhance GlyR function, and is known to act synergistically with ethanol to further 
potentiate glycine-activated currents (Cornelison et al. 2014, 2017).  It is therefore 
possible that Mascia and colleagues (1996) had greater concentrations of zinc 
contaminating their buffers.  It is also possible that we used different isoforms of the 1 
GlyR which may differ somewhat in function.  The human 1 isoform 2 lacks an 8-
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amino acid insertion in the intracellular domain that is present in isoform 1.  All of my 
experiments were performed using isoform 2 but it is unclear which isoform was used by 
Mascia and colleagues. 
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Fig 4:12 - Structural model of the zebrafish 1 GlyR showing W170 and W170S 
mutation 
 
Model of a single subunit of the homopentameric glycine-bound 1 GlyR showing the 
intra-subunit interaction between (A) W170 in Loop F (shown in blue) and A212 (shown 
in red).  (B) This interaction is disrupted by the W170S mutation (shown in blue). 
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Having observed a difference in ethanol modulation of low taurine currents at 
A52S 1 GlyR, I next compared currents produced by saturating concentrations of 
glycine and taurine and found that taurine produced peak current amplitudes that were 
~20% of those seen with glycine (Figure 4.7A).  This is significantly lower than WT 
indicating that the Po of taurine-bound receptors and therefore, the efficacy of taurine, is 
reduced by the A52S mutation.  I next co-applied saturating taurine with 200mM ethanol.  
Consistent with my hypothesis that the magnitude of allosteric modulation varies 
inversely with agonist efficacy, the degree of current enhancement by ethanol was 
substantially higher in the A52S mutant (Figure 4.7B). 
 Zinc is a biphasic modulator of GlyR function that is found ubiquitously in the 
central nervous system and as a contaminant in our buffers (Frederickson et al, 2006a, 
2006b; Hirzel et al, 2006; Cornelison and Mihic, 2014).  Since zinc can act in a 
synergistic manner with other modulators to alter GlyR function, I was concerned that 
some of the changes in ethanol modulation I had seen were due, in part, to differences in 
zinc sensitivity between A52S and WT receptors.  To rule this out, I measured zinc 
modulation of GlyR currents when activated by low (EC4-10) and saturating (100 mM) 
concentrations of taurine.  Co-application of taurine with potentiating (0.1 M & 1 M) 
and inhibiting (100 M) concentrations of zinc revealed no significant differences in zinc 
sensitivity between A52S and WT (Figure 4.8), thus confirming that the increase in 
taurine-evoked current potentiation seen with A52S was ethanol-specific.   
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 Recently, Cornelison et al., (2017) demonstrated the utility of the 1 W170S 
mutant, which is insensitive to enhancing concentrations of zinc, for assaying GlyR 
function without the confounding effects of zinc potentiation.  Expanding on this work, I 
characterized the effects of taurine and modulation of taurine-evoked activity at W170S 
1 GlyR.  First, I constructed taurine concentration-response curves for W170S and WT 
GlyR, that showed no significant difference between the two receptor types (Figure 4.9), 
which is in agreement with the findings of Zhou et al. (2013).  I then compared currents 
produced by saturating concentrations of taurine and glycine and found that the efficacy 
of taurine was comparable to glycine in the W170S mutant (Figure 4.10A).  This 
provided the opportunity to further validate my earlier hypothesis regarding the 
relationship between agonist efficacy and the magnitude of allosteric modulation.  If 
taurine is a high efficacy agonist, similar to glycine, at W170S then the Po of W170S 
GlyRs activated by high taurine concentrations should be close to 1 in the absence of any 
modulators.  According to this model, I would therefore not expect to see any 
enhancement by ethanol of maximally-effective taurine currents, which is what I found 
(Figure 4.10B). 
 Cornelison et al. (2017) found that the W170S 1 GlyR displayed a significantly 
lower ethanol response than WT receptors when activated by EC5-10 glycine in standard 
MBS buffer known to contain low nanomolar levels of contaminating zinc.  This 
difference between receptors was eliminated when the zinc chelator tricine was added to 
the buffers.  I performed similar experiments using EC5-10 taurine and also saw greater 
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ethanol modulation of WT currents than W170S when background zinc was present 
(Figure 4.11A) but this was no longer the case when using MBS that contained 2.5mM 
tricine (Figure 4.11B).   
Based to my hypothesis of an inverse relationship between the magnitude of 
allosteric modulation and agonist efficacy, one would have expected the enhancing 
effects of ethanol to be greater for WT than W170S receptors, even in the absence of zinc 
enhancement, if efficacy alone was being affected.  Due to the large increase in taurine 
efficacy caused by this mutation, the degree of allosteric modulation would be reduced 
relative to WT where taurine has much lower efficacy.  This was seen at saturating 
taurine concentrations (Fig. 4.10).  The fact that W170S 1 GlyR still show ethanol 
enhancement at low concentrations of taurine (Fig. 4.11) also suggests that ethanol acts to 
left-shift taurine-concentration response curves, similar to its effects on WT receptors. 
 The zinc-insensitive phenotype of W170S has been attributed to a disruption of a 
high-affinity zinc binding-site (Zhou et al., 2013).  This, however, does not explain the 
taurine-specific effects I observed.  Upon examining the crystal structure of the zebrafish 
1 glycine receptor from Du et al. (2015) in the glycine-bound state (3jae), I found that 
W170 is in close proximity to, and seems to interact with A212, a residue previously 
identified as being a key determinant in taurine activation of homomeric 1 GlyRs 
(Figure 4.12) (Schmieden et al. 1992).  Based on the structural model, this interaction 
may be disrupted in W170S GlyR, which may facilitate the conformational changes 
necessary to transduce taurine binding into channel gating (Figure 4.12).   
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Chapter 5: General Discussion, Conclusions and Future Directions 
5.1 – Overview 
Alcohol use disorders (AUDs) are one of the leading causes of preventable death, 
world-wide, and constitute a global economic burden.  Some of the effects of ethanol 
may be attributed to its role as an allosteric modulator of glycine receptors (GlyRs) in the 
central nervous system.  A better understanding how ethanol exerts its effects will 
provide insight into how alcohol use precipitates alcohol abuse and addiction and is 
crucial for the targeted development of therapies to combat addiction.  
Determining how ethanol exerts its effects on the human body is a highly 
complicated problem, in part due to the large variety of different receptors, receptor 
subtypes as well as other proteins, such as adenylyl cyclase, that are affected by 
pharmacologically-relevant concentrations of ethanol. The fact that chronic ethanol use 
or withdrawal can induce changes in the subunit composition of these receptors adds 
another layer of complexity. Furthermore, these receptors respond to multiple agonists 
and numerous allosteric modulators, which may act synergistically.  I sought to improve 
our overall understanding of how allosteric modulators influence receptor activity and 
provide insight into the mechanisms by which ethanol acts. 
Zinc is ubiquitous in the body with tonic levels in the nanomolar range known to 
potentiate GlyR currents.  It is also a common contaminant in our buffer at similar 
nanomolar concentrations.  McCracken et al. (2010) showed that zinc acts synergistically 
with ethanol to enhance GlyR currents to a degree greater than either modulator would in 
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isolation.  It is therefore important to consider the potential confounding effects of zinc 
when studying the effects of other allosteric modulators at these receptors.   
The data presented in this dissertation provide evidence supporting a novel 
mechanism by which modulation of glycine receptors by zinc, ethanol and perhaps other 
compounds depends on the efficacy of the agonist activating the receptor.  Furthermore, 
my research indicates that, in some cases, GlyR mutations that affect allosteric 
modulation do so by changing the efficacy of a particular agonist or agonists at the 
receptor.  Consequently, further research regarding allosteric modulation of GlyRs and, 
potentially, related receptors, will need to also account for such changes. 
5.2 – Allosteric Modulation of Wildtype Glycine Receptors 
The glycine receptor is activated by glycine and taurine, endogenous compounds 
which may each be the primary GlyR agonist in specific regions of the central nervous 
system (Albrecht and Schousboe, 2005, Mori et al., 2002).  Glycine is a high-efficacy 
agonist at the GlyR, with a Po of approximately 0.95 at saturating concentrations. In 
contrast, taurine has approximately 5% the efficacy of glycine and a Po of about 0.5 at 
maximally-effective taurine concentrations (Lape et al., 2008).  
Previous work in our lab showed that ethanol, anesthetics, inhalants, and zinc 
significantly enhance GlyR currents elicited by saturating concentrations of the partial 
agonist taurine but have no significant effects at high glycine concentrations (Kirson et 
al., 2012, 2013).  Biro et al. (2004) similarly observed a greater degree of allosteric 
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modulation of taurine- and -alanine-evoked GlyR currents by propofol, ganisetron, and 
the neurosteroid analogs minaxolone and alphaxalone than at glycine-gated receptors.   
Still, we know relatively little about the nature of allosteric modulation of currents 
produced by low concentrations of taurine compared with glycine. 
My initial goal was to characterize allosteric modulation of glycine receptors 
activated by low concentrations of taurine and see how it compared to modulation of 
similar currents gated by glycine.  I used the two-electrode voltage clamp (2EVC) 
method on Xenopus laevis oocytes expressing wild-type homomeric 1 or heteromeric 
 GlyR to measure the degree of enhancement of glycine- versus taurine-activated 
GlyR currents, in the presence of either zinc (100 nM & 2.5 M) or ethanol (50 mM and 
200 mM). 
 Allosteric modulators exhibit the greatest effects at low agonist concentrations 
(Beckstead et al., 2000; Miller et al., 2005; Welsh et al., 2010).  Based on prior 
experience, I expected to see greater potentiation of glycine currents because the 
concentration of glycine used fell much lower on its concentration response curve than 
the concentration of taurine needed to produce equivalent currents.  Contrary to my initial 
expectations, however, I found that a similar degree of zinc enhancement of currents 
produced by EC6.28 glycine and EC22.69 taurine at 1 homomeric GlyR.   
Upon further investigation, I saw concentration-dependent zinc potentiation of 
GlyR activity with greater potentiation, overall, of taurine than glycine currents (Figure 
3.4) and negligible effects at high concentrations of glycine.  The later was consistent 
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with previous data but the former was somewhat unexpected.  I later observed a similar 
pattern of modulation by EtOH at  heteromeric and 1 homomeric GlyRs.  This 
suggested that zinc and ethanol may be affecting GlyR currents via similar mechanisms 
and that allosteric modulators, in general, have greater activity at taurine-gated GlyRs.   
We know from single-channel studies that modulators such as ethanol enhance 
glycine affinity by antagonizing unbinding from the receptor (Welsh et al., 2009).  My 
data show that zinc and ethanol have very different effects when taurine is the agonist.   
Based on my own data and that of Kirson et al. (2012, 2013) it appears that zinc and 
ethanol increase the Po at glycine receptors activated by taurine, however, I observed a 
greater degree of zinc potentiation of taurine-evoked currents at lower EC values (Figure 
3.4).  Given this disparity in the degree of enhancement of currents produced by low and 
high concentrations of taurine, it seemed unlikely that only Po was being affected which 
led me to conclude that zinc was likely increasing taurine affinity at these lower EC 
values.  This reaffirms the idea that the mechanisms by which zinc and ethanol enhance 
wildtype GlyR function differ between glycine and taurine.    
5.3 – Role of Agonist Efficacy in Glycine Receptor Modulation 
Based on my earlier observations summarized in Chapter 3, I hypothesized that 
the observed disparity in the magnitude of allosteric modulation at wildtype glycine 
receptors is due to differences in efficacy between glycine and taurine.  There have been 
numerous studies comparing the effects of modulators, such as ethanol and zinc, on 
recombinant glycine receptors and GlyR mutants, but no one has studied whether 
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variations in alcohol sensitivity are in any way due to differences in agonist efficacy.  
This led me to wonder whether the results of our earlier experiments represent a 
generalizable mechanism for allosteric modulation of these receptors.   
GlyR mutations can affect a number of receptor characteristics including affinity, 
Po and the response to allosteric modulators.  Yet, no one has determined whether such 
differences in allosteric modulation result from mutation-induced changes in agonist 
efficacy.  I hypothesized that, if a receptor is mutated such that a given agonist becomes 
more or less efficacious, there will be a corresponding change in the degree of allosteric 
modulation. 
I tested this theory in Chapter 4 using mutant 1 GlyRs.  I initially focused on 
mutations in the Loop 2 region as these affect both agonist and ethanol sensitivity 
(Mascia et al., 1996; Naito et al., 2014; Perkins et al. 2008, 2012).  I examined a series of 
mutants, known as USERs, that were reported to have an enhanced sensitivity to low 
concentrations of ethanol when activated by glycine.  I also generated a number of 
mutations in the 1 GlyR based off of the USER sequence, hoping to pinpoint the 
specific residues responsible for these changes.  Despite the existence of several 
publications describing this ultra-low ethanol concentration sensitivity, I did not observe 
a similar effect in any of my mutants.  Furthermore, I were unable to reproduce the USER 
data from the literature. 
I next examined the effects of taurine at these USER mutants as this had not been 
previously investigated.  Although USERs 1 and 3 did not differ from wildtype in 
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response to maximally effective concentrations of taurine, USER2 had a lower taurine 
response relative to glycine, and increased enhancement of taurine currents by 200 mM 
ethanol.  Similarly, taurine had much lower efficacy relative to glycine at 1A52S GlyRs 
and exhibited a greater degree of ethanol potentiation, as we predicted.  I later determined 
that these changes were not due to a difference in zinc modulation at A52S, confirming 
that these effects were ethanol-specific.  
Cornelison et al. (2017) recently validated the use of the 1W170S mutant, which is 
insensitive to zinc potentiation, as a model for studying the effects of ethanol at GlyRs 
without the additional need to account for zinc contamination.  In addition to its zinc 
insensitivity, W170S shows an enhanced taurine response.  When I compared peak 
currents produced by maximally-effective concentrations of glycine and taurine, I found 
that taurine efficacy was comparable to that of glycine at W170S.  I next examined the 
effects of 200 mM ethanol on saturating taurine W170S and WT GlyR.  As expected, this 
drastic increase in taurine efficacy at W170S was accompanied by a significant reduction 
in ethanol potentiation which further supports my proposed mechanism.  
5.4 – Future Directions 
My work demonstrated that the nature of allosteric modulation of glycine 
receptors differs depending on the efficacy of the agonist gating the receptor.  Based on 
my experiments with wildtype, USER2, A52S and W170S, I propose that there is an 
inverse relationship between agonist efficacy and allosteric modulation of glycine 
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receptors which should be addressed in any subsequent studies of glycine receptor 
modulation.    
It is important to keep in mind that my measurements of taurine efficacy were all 
made relative to the activity of glycine.  It could thus be argued that in some cases it 
wasn't necessarily taurine efficacy that went up, but instead that glycine efficacy went 
down.  Single-channel recordings could distinguish between these two possibilities and 
should be performed in order to construct kinetic models that can be used to quantify 
agonist efficacies and open channel probabilities to further validate our model.  Thus far, 
I have only explored modulation of glycine receptors.  Additional experiments will need 
to be carried out to determine whether this mechanism is generalizable to other receptors. 
It has yet to be determined how the W170S mutation causes such a dramatic 
change in taurine efficacy at these receptors.  I proposed that disrupting intra-subunit 
interaction between W170 and A212 may be an important step in taurine-gating of the 
glycine receptor.  Mutagenesis studies exploring the effects of different tertiary 
interactions between these regions of the protein would help confirm or disprove this 
hypothesis.   
Structures of the GlyR in the active state are currently only available for glycine- 
and strychnine-bound receptors.  The future availability of a taurine-bound GlyR 
structure would greatly enhance our understanding of the agonist-specific differences in 
conformation that follow glycine- vs. taurine-mediated activation of glycine receptors, 
and elucidate how these contribute to the functional disparities that are observed. 
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